{"content":"<li class=\"n-box-item date-title\" data-end=\"1513745999\" data-start=\"1513659600\" data-txt=\"Monday, December 23, 2019\">Tuesday, December 19, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3319306\" data-ts=\"1513732028\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/COINB\" target=\"_blank\">COINB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319306-bitcoin-cash-soars-coinbase-adds\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bitcoin Cash soars as Coinbase adds</a></h4><ul><li>Bitcoin Cash has been on a big run for the past few days on rumor it was soon to be available for trade on popular exchange Coinbase (<a href='https://seekingalpha.com/symbol/COINB' title='Coinbase'>COINB</a>). Sure enough, it's happened, with <a href=\"https://blog.coinbase.com/buy-sell-send-and-receive-bitcoin-cash-on-coinbase-65f1b2c7214b\" target=\"_blank\">BCH joining</a> Bitcoin, Ether, and Litecoin on the Coinbase platform.</li><li>BCH has&nbsp;<font color='green'>jumped nearly another 20%</font>&nbsp;over the past hour, and at $3,191 is&nbsp;<font color='green'>roughly double</font>&nbsp;its price from Friday. Bitcoin, Ether, and Litecoin, on the other hand, are all selling off this evening. And the Coinbase site? It's crashed again.</li><li>Related tickers: <a href='https://seekingalpha.com/symbol/GBTC' title='Grayscale Bitcoin Trust &#40;BTC&#41;'>OTCQX:GBTC</a>, <a href='https://seekingalpha.com/symbol/COIN' title='Winklevoss Bitcoin Trust ETF'>COIN</a>, <a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a>, <a href='https://seekingalpha.com/symbol/OSTK' title='Overstock.com, Inc.'>OSTK</a>, <a href='https://seekingalpha.com/symbol/SSC-OLD' title='Seven Stars Cloud Group, Inc.'>SSC-OLD</a>, <a href='https://seekingalpha.com/symbol/MARA' title='Marathon Patent Group, Inc.'>MARA</a>, <a href='https://seekingalpha.com/symbol/UEPS' title='Net 1 UEPS Technologies, Inc.'>UEPS</a>, <a href='https://seekingalpha.com/symbol/BITCF' title='First Bitcoin Capital Corp.'>OTC:BITCF</a>, <a href='https://seekingalpha.com/symbol/XNET' title='Xunlei Limited'>XNET</a>, <a href='https://seekingalpha.com/symbol/GROW' title='U.S. Global Investors, Inc.'>GROW</a>, <a href='https://seekingalpha.com/symbol/BTSC' title='Bitcoin Services, Inc.'>OTCPK:BTSC</a>, <a href='https://seekingalpha.com/symbol/BTCS' title='BTCS Inc.'>OTCQB:BTCS</a>, <a href='https://seekingalpha.com/symbol/MGTI' title='MGT Capital Investments, Inc.'>OTCQB:MGTI</a>, <a href='https://seekingalpha.com/symbol/SRAX' title='Social Reality Inc.'>SRAX</a>, <a href='https://seekingalpha.com/symbol/GAHC' title='Global Arena Holding, Inc.'>OTCPK:GAHC</a>, <a href='https://seekingalpha.com/symbol/UBIA' title='UBI BlockChain Internet Ltd.'>OTC:UBIA</a>, <a href='https://seekingalpha.com/symbol/ARSC' title='American Security Resources Corp.'>OTC:ARSC</a>, <a href='https://seekingalpha.com/symbol/USTC' title='USA Real Estate Holding Co'>OTCPK:USTC</a>, PRELF, <a href='https://seekingalpha.com/symbol/BLKCF' title='Global Blockchain Technologies Corp.'>OTCPK:BLKCF</a>, <a href='https://seekingalpha.com/symbol/CRCW' title='The Crypto Company'>OTC:CRCW</a>, <a href='https://seekingalpha.com/symbol/COINB' title='Coinbase'>COINB</a>, <a href='https://seekingalpha.com/symbol/LFIN' title='LongFin Corp.A'>OTCPK:LFIN</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3319306\" data-linked=\"Bitcoin Cash soars as Coinbase adds\" data-tweet=\"$COINB $COINB $GBTC - Bitcoin Cash soars as Coinbase adds https://seekingalpha.com/news/3319306-bitcoin-cash-soars-coinbase-adds?source=tweet\" data-url=\"https://seekingalpha.com/news/3319306-bitcoin-cash-soars-coinbase-adds\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>106&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319290\" data-ts=\"1513722938\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319290-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers:</b> <a href='https://seekingalpha.com/symbol/MU' title='Micron Technology Inc.'>MU</a> <font color='green'>+5.1%</font>. <a href='https://seekingalpha.com/symbol/TA' title='TravelCenters of America LLC'>TA</a> <font color='green'>+2.5%</font>. <a href='https://seekingalpha.com/symbol/IONS' title='Ionis Pharmaceuticals, Inc.'>IONS</a> <font color='green'>+2.1%</font>. <a href='https://seekingalpha.com/symbol/ITCB' title='Itau CorpBanca'>ITCB</a> <font color='green'>+1.5%</font>. <a href='https://seekingalpha.com/symbol/FDX' title='FedEx Corporation'>FDX</a> <font color='green'>+1.4%</font>.</li><li><b>Top losers:</b> <a href='https://seekingalpha.com/symbol/CCIH' title='ChinaCache International'>CCIH</a> <font color='red'>-11.5%</font>. <a href='https://seekingalpha.com/symbol/SFIX' title='Stitch Fix, Inc.'>SFIX</a> <font color='red'>-10.3%</font>. <a href='https://seekingalpha.com/symbol/SCS' title='Steelcase Inc.'>SCS</a> <font color='red'>-9.4%</font>. <a href='https://seekingalpha.com/symbol/INTX' title='Intersections, Inc.'>INTX</a> <font color='red'>-8.7%</font>. <a href='https://seekingalpha.com/symbol/APEN' title='Apollo Endosurgery'>APEN</a> <font color='red'>-7.5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3319290\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$MU $TA $IONS - After Hours Gainers / Losers https://seekingalpha.com/news/3319290-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3319290-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319289\" data-ts=\"1513722575\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SFIX\" target=\"_blank\">SFIX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319289-stitch-fixminus-11-in-first-earnings-report-public-company\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stitch Fix -11% in first earnings report as public company</a></h4><ul>     <li>Stitch Fix (NASDAQ:<a href='https://seekingalpha.com/symbol/SFIX' title='Stitch Fix, Inc.'>SFIX</a>) <font color='red'>-11.1%</font> after-hours following its first earnings report as a publicly traded company, with <a href=\"https://seekingalpha.com/news/3319249-stitch-fix-beats-0_01-beats-revenue\" target=\"_blank\">FQ1 (Oct.) earnings</a> and revenues edging analyst expectations.</li>     <li>However, SFIX says <a href=\"https://www.cnbc.com/2017/12/19/stitch-fix-q1-earnings-2018.html\" target=\"_blank\">gross margins fell</a> nearly three percentage points, hurt by investments into new categories, and the company says it  continues to expect profit margins to decline in the near term as those investments ramp up.</li>     <li>SFIX says its active client count in the quarter jumped nearly 30% to 2.4M users as of Oct. 28.</li>     <li>Net revenue per active client for the 12 months ended Oct. 28 was $433, 1.4% lower than in the year ended Oct. 29, 2016.</li>     <li>SFIX issues upside revenue guidance for Q2, forecasting $287M-$294M vs. $286M analyst consensus, but sees EBITDA of $11.5M-$15.5M vs. $16M consensus.</li>     <li>For FY 2018, the company sees revenues of $1.17B-$1.22B vs. $1.18B consensus and EBITDA of $40M-$60M vs. $57.5M consensus.</li></ul><div class=\"tiny-share-widget\" data-id=\"3319289\" data-linked=\"Stitch Fix -11% in first earnings report as public company\" data-tweet=\"$SFIX - Stitch Fix -11% in first earnings report as public company https://seekingalpha.com/news/3319289-stitch-fixminus-11-in-first-earnings-report-public-company?source=tweet\" data-url=\"https://seekingalpha.com/news/3319289-stitch-fixminus-11-in-first-earnings-report-public-company\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319278\" data-ts=\"1513720634\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GALT\" target=\"_blank\">GALT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319278-galectin-secures-10m-credit-line-shares-ahead-30-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Galectin secures $10M credit line; shares ahead 30% after hours</a></h4><ul><li>Nano cap Galectin Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/GALT' title='Galectin Therapeutics, Inc.'>GALT</a>) is up&nbsp;<font color='green'>30%</font>&nbsp;after hours on increased volume on the heels of its <a href=\"https://seekingalpha.com/pr/17030977-galectin-therapeutics-announces-10-million-credit-line-richard-e-uihlein-sufficient-cover\" target=\"_blank\">announcement </a>that it has inked a $10M unsecured credit facility with new director Richard Uihlein.</li><li>Under the terms of the facility, the company can borrow at its discretion through year-end 2018.</li><li>In consideration of the credit line, Mr. Uihlein received warrants to purchase up to 1M common shares at $5.00 per share.</li></ul><div class=\"tiny-share-widget\" data-id=\"3319278\" data-linked=\"Galectin secures $10M credit line; shares ahead 30% after hours\" data-tweet=\"$GALT - Galectin secures $10M credit line; shares ahead 30% after hours https://seekingalpha.com/news/3319278-galectin-secures-10m-credit-line-shares-ahead-30-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3319278-galectin-secures-10m-credit-line-shares-ahead-30-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>28&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319274\" data-ts=\"1513720166\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RHT\" target=\"_blank\">RHT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319274-red-hatminus-3_9-despite-q3-beats-upside-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Red Hat -3.9% despite Q3 beats, upside guidance</a></h4><ul><li>           Red Hat (NYSE:<a href='https://seekingalpha.com/symbol/RHT' title='Red Hat, Inc.'>RHT</a>) shares are&nbsp;<font color='red'>down 3.9%</font>&nbsp;aftermarket despite Q3 results that beat EPS and revenue estimates. Upside Q4 guidance has revenue from $758M to $763M (consensus: $748.91M) and EPS at $0.81 (consensus: $0.75). </li><li> More Q4 guidance: GAAP operating margin, 16.7%; non-GAAP operating margin, 24.6%. </li><li> Upside FY18 guidance: revenue, $2.906B to $2.911B (consensus: $2.88B); GAAP operating margin, 16.1%; non-GAAP operating margin, 23.9%; EPS, $2.88 (consensus: $2.78). </li><li> Subscription revenue breakout: Infrastructure-related offerings, $495M (+14% Y/Y in constant currency); Application Development-related and other emerging tech, $162M (+42%).&nbsp; </li><li>           Key metrics: GAAP operating margin, 15.8% (guidance: 15.2%); deferred revenue, $2.11B (+19% Y/Y); operating cash flow, $160M (+18%); cash and equivalents, $2.32B. &nbsp; </li><li>        <a href=\"https://seekingalpha.com/pr/17030990-red-hat-reports-third-quarter-results-fiscal-year-2018\" target=\"_blank\">Press release</a></li><li>Listen to Red Hat's earnings call at 5 p.m. ET <a href=\"http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Finvestors.redhat.com%2F&amp;esheet=51732286&amp;newsitemid=20171219005948&amp;lan=en-US&amp;anchor=http%3A%2F%2Finvestors.redhat.com&amp;index=1&amp;md5=1db4704ad325afcc162c887dd9f4a1a4\" target=\"_blank\">here.</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3319256-red-hat-beats-0_03-beats-revenue\" target=\"_blank\">Red Hat beats by $0.03, beats on revenue</a> (Dec. 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3319274\" data-linked=\"Red Hat -3.9% despite Q3 beats, upside guidance\" data-tweet=\"$RHT - Red Hat -3.9% despite Q3 beats, upside guidance https://seekingalpha.com/news/3319274-red-hatminus-3_9-despite-q3-beats-upside-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3319274-red-hatminus-3_9-despite-q3-beats-upside-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:49 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>25&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319261\" data-ts=\"1513718808\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MU\" target=\"_blank\">MU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319261-micronplus-3_1-after-q1-beats-upside-eps-and-nand-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Micron +3.1% after Q1 beats, upside EPS and NAND guidance</a></h4><ul><li>        Micron Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/MU' title='Micron Technology Inc.'>MU</a>) shares are up 3.1% aftermarket following Q1 results that beat EPS and revenue estimates. Q2 guidance has revenue from $6.8B to $7.2B (consensus: $6.21B) and EPS from $2.51 to $2.65 (consensus: $2.03).</li><li>               DRAM guidance: CY18 industry supply bit growth expected at about 20% and Micron expects FY18 to come in slightly below that figure.&nbsp;</li><li>               NAND guidance: CY18 industry supply bit growth expected at about 50% and Micron expects to come in &ldquo;somewhat above&rdquo; the industry.&nbsp;</li><li>               Key metrics: Gross margin, 55.1% (guidance: 50% to 54%); operating income, $3.09B (guidance: $2.65B to $2.85B); operating expenses, $650M (guidance $575M to $625M); cash and equivalents, $6.2B; current debt, $1.4B.&nbsp;</li><li>               <a href=\"https://seekingalpha.com/pr/17030941-micron-technology-inc-reports-results-first-quarter-fiscal-2018\" target=\"_blank\">Press release </a>&nbsp;/ <a href=\"http://files.shareholder.com/downloads/ABEA-45YXOQ/5596172130x0x967084/152C900F-8D11-4AB0-839F-D6E298060B58/Micron_FQ1-2018_Earnings_Call_Presentation_Slides.pdf\" target=\"_blank\">Presentation slides</a>&nbsp;</li><li>                  Micron&rsquo;s earnings call starts at 4:30 p.m. ET <a href=\"http://investors.micron.com/eventdetail.cfm?accepted=yes&amp;EventID=186502\" target=\"_blank\">here</a>.&nbsp;&nbsp;&nbsp; </li><li>Previously: <a href=\"https://seekingalpha.com/news/3319242-micron-technology-beats-0_25-beats-revenue\" target=\"_blank\">Micron Technology beats by $0.25, beats on revenue</a> (Dec. 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3319261\" data-linked=\"Micron +3.1% after Q1 beats, upside EPS and NAND guidance\" data-tweet=\"$MU - Micron +3.1% after Q1 beats, upside EPS and NAND guidance https://seekingalpha.com/news/3319261-micronplus-3_1-after-q1-beats-upside-eps-and-nand-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3319261-micronplus-3_1-after-q1-beats-upside-eps-and-nand-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:26 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>177&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319260\" data-ts=\"1513718709\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FDX\" target=\"_blank\">FDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319260-fedex-zooms-higher-after-strong-profit-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FedEx zooms higher after strong profit guidance</a></h4><ul>     <li>FedEX (NYSE:<a href='https://seekingalpha.com/symbol/FDX' title='FedEx Corporation'>FDX</a>) tracks higher in AH trading after a strong FQ2 report.</li>     <li>Adjusted operating margin improved 30 bps to 8.5% during the quarter.</li>     <li>Investors have their eyes focused on the strong profit guidance from the shipper.&nbsp;FedEx guided for FY18 EPS of $12.70 to $13.30 vs. $12.00 to $12.80 prior and $12.48 consensus,</li><li>Shares of FedEX are&nbsp;<font color='green'>up 2.50%</font>&nbsp;AH.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3319253-fedex-beats-0_29-beats-revenue\" target=\"_blank\">FedEx beats by $0.29, beats on revenue</a> (Dec. 19)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3319260\" data-linked=\"FedEx zooms higher after strong profit guidance\" data-tweet=\"$FDX - FedEx zooms higher after strong profit guidance https://seekingalpha.com/news/3319260-fedex-zooms-higher-after-strong-profit-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3319260-fedex-zooms-higher-after-strong-profit-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319253\" data-ts=\"1513718156\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FDX\" target=\"_blank\">FDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319253-fedex-beats-0_29-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FedEx beats by $0.29, beats on revenue</a></h4><ul><li>FedEx (NYSE:<a href='https://seekingalpha.com/symbol/FDX' title='FedEx Corporation'>FDX</a>): Q2 EPS of $3.18 <font color='green'>beats by $0.29</font>.</li><li>Revenue of $16.3B (+9.2% Y/Y) <font color='green'>beats by $620M</font>.</li><li>Shares <font color='green'>+1.5%</font>.</li><li><a href='https://seekingalpha.com/pr/17030988-fedex-corp-reports-higher-second-quarter-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3319253\" data-linked=\"FedEx beats by $0.29, beats on revenue\" data-tweet=\"$FDX - FedEx beats by $0.29, beats on revenue https://seekingalpha.com/news/3319253-fedex-beats-0_29-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3319253-fedex-beats-0_29-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:15 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319239\" data-ts=\"1513717110\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IO\" target=\"_blank\">IO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319239-ion-geophysicalplus-23-ceo-hanson-buys-36k-plus-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ion Geophysical +23% as CEO Hanson buys 36K-plus shares</a></h4><ul><li>Ion Geophysical (<a href='https://seekingalpha.com/symbol/IO' title='ION Geophysical Corporation'>IO</a> <font color='green'>+23.4%</font>) surges to a 52-week high after President and CEO Brian Hanson discloses the <a href=\"https://www.streetinsider.com/SEC+Filings/Form+4+ION+GEOPHYSICAL+CORP+For%3A+Dec+14+Filed+by%3A+Hanson+R+Brian/13612544.html\" target=\"_blank\">purchase of 36,351 shares</a> at an average price of $13.05 each, for a total purchase of nearly $475K.</li><li>Hanson now owns nearly 155K shares of the company's common stock.</li><li>At least six other insiders, including IO's CFO and Senior VP also bought shares late last week.</li></ul><div class=\"tiny-share-widget\" data-id=\"3319239\" data-linked=\"Ion Geophysical +23% as CEO Hanson buys 36K-plus shares\" data-tweet=\"$IO - Ion Geophysical +23% as CEO Hanson buys 36K-plus shares https://seekingalpha.com/news/3319239-ion-geophysicalplus-23-ceo-hanson-buys-36k-plus-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3319239-ion-geophysicalplus-23-ceo-hanson-buys-36k-plus-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319235\" data-ts=\"1513715878\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LOGM\" target=\"_blank\">LOGM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319235-logmein-provides-financial-outlook-for-fy18-fy20\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">LogMeIn provides financial outlook for FY18, FY20</a></h4><ul><li>        LogMeIn (NASDAQ:<a href='https://seekingalpha.com/symbol/LOGM' title='LogMeIn, Inc.'>LOGM</a>) provides FY18 and FY20 <a href=\"http://www.briefing.com/DisplayArticle/ArticlePopup.aspx?ArticleId=IN20171219111240LOGM\" target=\"_blank\">financial outlooks</a> at its Investor Day.</li><li>                  FY18 organic outlook: revenue, $1.135B to $1.15B (may not compare to the $1.17B consensus); EBITDA, $440M; FCF, $375M.    </li><li>FY20 target: revenue, $1.25B to $1.325B; EBITDA, $525M; FCF, $450M.&nbsp;</li><li>               LogMeIn shares are&nbsp;<font color='red'>down 2.7%</font>. &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3319235\" data-linked=\"LogMeIn provides financial outlook for FY18, FY20\" data-tweet=\"$LOGM - LogMeIn provides financial outlook for FY18, FY20 https://seekingalpha.com/news/3319235-logmein-provides-financial-outlook-for-fy18-fy20?source=tweet\" data-url=\"https://seekingalpha.com/news/3319235-logmein-provides-financial-outlook-for-fy18-fy20\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:37 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319233\" data-ts=\"1513714781\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/YGE\" target=\"_blank\">YGE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319233-yingli-green-energyminus-7-after-quarterly-shipments-slump-48\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Yingli Green Energy -7% after quarterly shipments slump 48%</a></h4><ul>     <li>Yingli Green Energy (<a href='https://seekingalpha.com/symbol/YGE' title='Yingli Green Energy Holding Company Limited'>YGE</a> <font color='red'>-7%</font>) thuds to a 52-week low after reporting a wider than expected <a href=\"https://seekingalpha.com/news/3319070-yingli-green-energy-misses-0_09-beats-revenue\" target=\"_blank\">Q3 loss</a> to RMB2.3B ($355M) from a RMB335M loss a year earlier.</li>     <li>YGE says its Q3 PV module shipments fell 48% Q/Q to  597.7 MW vs. guidance for 550-600 MW, compared to 1,146 MW in Q2.</li>     <li>Chairman/CEO Liansheng Miao attributes the fall in quarterly shipments to <a href=\"https://www.pv-magazine.com/2017/12/19/yingli-posts-355-million-net-loss-in-q3/\" target=\"_blank\">lower demand</a> from the end of H1, saying YGE tried to strike a balance between maintaining shipment volumes and ensuring that its operating cash flows remained sufficient.</li>     <li>YGE expects Q4 PV module shipments of 700-800 MW, and raises its full year PV module shipments guidance to 2.8-2.9 GW from its previous 2.5-2.8 GW.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3319233\" data-linked=\"Yingli Green Energy -7% after quarterly shipments slump 48%\" data-tweet=\"$YGE - Yingli Green Energy -7% after quarterly shipments slump 48% https://seekingalpha.com/news/3319233-yingli-green-energyminus-7-after-quarterly-shipments-slump-48?source=tweet\" data-url=\"https://seekingalpha.com/news/3319233-yingli-green-energyminus-7-after-quarterly-shipments-slump-48\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:19 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319230\" data-ts=\"1513714314\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EXEL\" target=\"_blank\">EXEL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319230-fda-oks-exelixis-cabometyx-for-first-line-kidney-cancer-shares-ahead-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs Exelixis&#39; Cabometyx for first-line kidney cancer; shares ahead 3%</a></h4><ul><li>Under Priority Review status, the FDA <a href=\"https://seekingalpha.com/pr/17030892-exelixis-announces-u-s-fda-approval-cabometyx-cabozantinib-tablets-previously-untreated\" target=\"_blank\">approves </a>the use of Exelixis' (<a href='https://seekingalpha.com/symbol/EXEL' title='Exelixis, Inc.'>EXEL</a> <font color='green'>+2.6%</font>) CABOMETYX (cabozantinib) for the treatment of patients with advanced renal cell carcinoma &#40;RCC&#41; in a first-line setting. The agency's action date was February 25, 2018.</li><li>The data supporting the application was generated in the Phase 2 CABOSUN study which showed treatment with cabozantinib statistically significantly extended progression-free survival compared to standard-of-care treatment with Pfizer's SUTENT (sunitinib malate).</li><li>CABOMETYX was first approved in the U.S. in April 2016 for RCC in a second-line setting.</li></ul><div class=\"tiny-share-widget\" data-id=\"3319230\" data-linked=\"FDA OKs Exelixis&#39; Cabometyx for first-line kidney cancer; shares ahead 3%\" data-tweet=\"$EXEL - FDA OKs Exelixis&#39; Cabometyx for first-line kidney cancer; shares ahead 3% https://seekingalpha.com/news/3319230-fda-oks-exelixis-cabometyx-for-first-line-kidney-cancer-shares-ahead-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3319230-fda-oks-exelixis-cabometyx-for-first-line-kidney-cancer-shares-ahead-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:11 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319231\" data-ts=\"1513714299\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AKAM\" target=\"_blank\">AKAM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319231-craig-hallum-upgrades-akamai-on-activist-investor\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Craig-Hallum upgrades Akamai on activist investor</a></h4><ul><li>        Craig-Hallum <a href=\"https://www.streetinsider.com/Upgrades/Craig-Hallum+Upgrades+Akamai+Technologies+%28AKAM%29+to+Buy%2C+Activist+Arrival+Reshapes+Risk+Reward/13615420.html\" target=\"_blank\">upgrades</a> Akamai Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/AKAM' title='Akamai Technologies, Inc.'>AKAM</a>) from Neutral to Buy with an $80 price target.</li><li>               The firm says that the arrival of activist investor Elliott Associates reshapes Akamai&rsquo;s risk-reward balance. &nbsp;&nbsp;</li><li>               Akamai shares are<font color='green'> up 2.5%</font>.&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3318724-akamai-plus-10_7-percent-active-stake-reveal\" target=\"_blank\">Akamai +10.7% after active stake reveal</a> (Dec. 15)</li></ul><div class=\"tiny-share-widget\" data-id=\"3319231\" data-linked=\"Craig-Hallum upgrades Akamai on activist investor\" data-tweet=\"$AKAM - Craig-Hallum upgrades Akamai on activist investor https://seekingalpha.com/news/3319231-craig-hallum-upgrades-akamai-on-activist-investor?source=tweet\" data-url=\"https://seekingalpha.com/news/3319231-craig-hallum-upgrades-akamai-on-activist-investor\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:11 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319228\" data-ts=\"1513713530\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDR\" target=\"_blank\">MDR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319228-mcdermott-cbi-plunge-in-reaction-to-merger-nobody-seems-to-like\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">McDermott, CBI plunge in reaction to merger nobody seems to like</a></h4><ul>     <li>McDermott (<a href='https://seekingalpha.com/symbol/MDR' title='McDermott International, Inc.'>MDR</a> <font color='red'>-9.9%</font>) and CB&amp;I (<a href='https://seekingalpha.com/symbol/CBI' title='Chicago Bridge & Iron Company'>CBI</a> <font color='red'>-7.9%</font>) are both sharply lower as investors of both companies <a href=\"https://www.barrons.com/articles/wow-the-market-really-doesnt-like-this-deal-1513703900\" target=\"_blank\">register their displeasure</a> with MDR's <a href=\"https://seekingalpha.com/news/3319018-mcdermott-cb-merge-6b-deal\" target=\"_blank\">$6B acquisition</a> of CBI.</li>     <li>The market appears to have been taken by surprise, with MKM analyst Daniel Scott saying \"the combination wasn't what we expected.\"</li>     <li>At 2.47221 per MDR share, the company is acquiring CBI at essentially no premium but MDR shareholders are wary of the deal because CBI's litany of problems with construction deadlines and cost overruns.</li>     <li>Motley Fool's Rich Smith calculates the two companies together carrying a <a href=\"https://finance.yahoo.com/news/why-mcdermott-international-shares-dropped-174656575.html\" target=\"_blank\">combined net debt load approaching $1.8B</a>, and instead of generating cash to pay off the debt, burning through a combined $522M in negative free cash flow over the past year.</li>     <li>The companies say they are <a href=\"https://www.bloomberg.com/gadfly/articles/2017-12-19/mcdermott-cb-i-deal-cheap-for-a-reason\" target=\"_blank\">targeting $250M of cost savings</a>, with some coming from a 16% reduction in the combined  companies' rather vague \"other business related costs\" in addition to&nbsp;the standard  G&amp;A expense streamlining, supply-chain savings  and operations optimization.</li>     <li>As for CBI, the deal likely is as good as could be expected, but its execution challenges <a href=\"https://thefly.com/thestreet/realmoney/index.php/CBI%3bMDRid2656976/CBI%3bMDR-CBI-downgraded-to-Neutral-from-Buy-at-DA-Davidson\" target=\"_blank\">reduce the likelihood of a competitive bid</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3319228\" data-linked=\"McDermott, CBI plunge in reaction to merger nobody seems to like\" data-tweet=\"$MDR $MDR $CBI - McDermott, CBI plunge in reaction to merger nobody seems to like https://seekingalpha.com/news/3319228-mcdermott-cbi-plunge-in-reaction-to-merger-nobody-seems-to-like?source=tweet\" data-url=\"https://seekingalpha.com/news/3319228-mcdermott-cbi-plunge-in-reaction-to-merger-nobody-seems-to-like\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>32&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319226\" data-ts=\"1513713364\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319226-technology-top-gainers-losers-of-2-55-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 2:55 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CCIH' title='ChinaCache International'>CCIH</a> <font color='green'>+140%</font>. <a href='https://seekingalpha.com/symbol/MEET' title='The Meet Group, Inc.'>MEET</a> <font color='green'>+29%</font>. <a href='https://seekingalpha.com/symbol/TEUM' title='Pareteum Corporation'>TEUM</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/BOSC' title='B.O.S. Better Online Solutions'>BOSC</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/KONE' title='Kingtone Wirelessinfo Solution Holding Ltd'>KONE</a> <font color='green'>+13%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/GLUU' title='Glu Mobile Inc.'>GLUU</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/FTR' title='Frontier Communications Corporation'>FTR</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/XNET' title='Xunlei Limited'>XNET</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/DPW' title='DPW Holdings, Inc.'>DPW</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/FDS' title='FactSet Research Systems Inc.'>FDS</a> <font color='red'>-9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3319226\" data-linked=\"Technology - Top Gainers / Losers as of 2:55 pm\" data-tweet=\"$CCIH $MEET $TEUM - Technology - Top Gainers / Losers as of 2:55 pm https://seekingalpha.com/news/3319226-technology-top-gainers-losers-of-2-55-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3319226-technology-top-gainers-losers-of-2-55-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319218\" data-ts=\"1513711021\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NLY\" target=\"_blank\">NLY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319218-mortgage-reits-lower-yields-break-out-to-upside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mortgage REITs lower as yields break out to the upside</a></h4><ul><li>The 10-year Treasury yield had been holding in a fairly tight range of about 2.30-2.37% for the past couple of months, but has shot up to 2.47% today - it's highest level since early March.</li><li>Helping today's move higher in yields <a href=\"https://seekingalpha.com/news/3319161-new-leg-higher-yields-fast-housing-starts-print\" target=\"_blank\">was a strong housing starts </a>report for November.</li><li>The mortgage REITs (<a href='https://seekingalpha.com/symbol/REM' title='iShares Mortgage Real Estate Capped ETF'>REM</a> <font color='red'>-4.3%</font>) - many trading at negligible discounts to book value, if not premiums - are lower across the board, led by Annaly Capital (<a href='https://seekingalpha.com/symbol/NLY' title='Annaly Capital Management, Inc.'>NLY</a> <font color='red'>-1.6%</font>) and AGNC Investment (<a href='https://seekingalpha.com/symbol/AGNC' title='AGNC Investment Corp.'>AGNC</a> <font color='red'>-1.8%</font>).</li><li>Among other names: Armour (<a href='https://seekingalpha.com/symbol/ARR' title='ARMOUR Residential REIT, Inc.'>ARR</a> <font color='red'>-1.9%</font>), CYS (<a href='https://seekingalpha.com/symbol/CYS' title='CYS Investments, Inc.'>CYS</a> <font color='red'>-2%</font>), Western Asset (<a href='https://seekingalpha.com/symbol/WMC' title='Western Asset Mortgage Capital Corporation'>WMC</a> <font color='red'>-1.2%</font>), Capstead (<a href='https://seekingalpha.com/symbol/CMO' title='Capstead Mortgage Corporation'>CMO</a> <font color='red'>-1.5%</font>), MFA Financial (<a href='https://seekingalpha.com/symbol/MFA' title='MFA Financial, Inc.'>MFA</a> <font color='red'>-1.5%</font>), Dynex (<a href='https://seekingalpha.com/symbol/DX' title='Dynex Capital Inc.'>DX</a> <font color='red'>-1.4%</font>)</li><li>ETFs: <a href='https://seekingalpha.com/symbol/MORL' title='UBS ETRACS Monthly Pay 2x Leveraged Mortgage REIT ETN'>MORL</a>, <a href='https://seekingalpha.com/symbol/REM' title='iShares Mortgage Real Estate Capped ETF'>REM</a>, <a href='https://seekingalpha.com/symbol/MORT' title='VanEck Vectors Mortgage REIT Income ETF'>MORT</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3319218\" data-linked=\"Mortgage REITs lower as yields break out to the upside\" data-tweet=\"$NLY $REM $NLY - Mortgage REITs lower as yields break out to the upside https://seekingalpha.com/news/3319218-mortgage-reits-lower-yields-break-out-to-upside?source=tweet\" data-url=\"https://seekingalpha.com/news/3319218-mortgage-reits-lower-yields-break-out-to-upside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319213\" data-ts=\"1513710173\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319213-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/IO' title='ION Geophysical Corporation'>IO</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/MCF' title='Contango Oil & Gas Company'>MCF</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/SDPI' title='Superior Drilling Products, Inc.'>SDPI</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/BXE' title='Bellatrix Exploration Ltd'>BXE</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/EPE' title='EP Energy Corporation'>EPE</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/YTEN' title='Yield10 Bioscience, Inc.'>YTEN</a> <font color='red'>-27%</font>. <a href='https://seekingalpha.com/symbol/MDR' title='McDermott International, Inc.'>MDR</a> <font color='red'>-10%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3319213\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$IO $MCF $SDPI - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3319213-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3319213-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319207\" data-ts=\"1513708522\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NWBO\" target=\"_blank\">NWBO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319207-northwest-bio-launches-convertible-stock-offering-shares-down-5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Northwest Bio launches convertible stock offering; shares down 5%</a></h4><ul><li>Northwest Biotherapeutics (<a href='https://seekingalpha.com/symbol/NWBO' title='Northwest Biotherapeutics, Inc.'>OTCQB:NWBO</a> <font color='red'>-4.5%</font>) commences an offering of Series B Convertible Preferred Stock under the SEC's <a href=\"https://www.sec.gov/fast-answers/answers-regdhtm.html\" target=\"_blank\">Regulation D</a> which allows exemptions from registration requirements.</li><li>Each Series B share, priced at $2.30, will be convertible into 10 common shares at $0.23. Buyers will also receive two-year warrants to purchase up to 10 common shares per Series B share acquired, exercisable at $0.30 per common share.</li><li>Closing date of the general solicitation is December 29.</li></ul><div class=\"tiny-share-widget\" data-id=\"3319207\" data-linked=\"Northwest Bio launches convertible stock offering; shares down 5%\" data-tweet=\"$NWBO - Northwest Bio launches convertible stock offering; shares down 5% https://seekingalpha.com/news/3319207-northwest-bio-launches-convertible-stock-offering-shares-down-5?source=tweet\" data-url=\"https://seekingalpha.com/news/3319207-northwest-bio-launches-convertible-stock-offering-shares-down-5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>37&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319204\" data-ts=\"1513707730\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAN\" target=\"_blank\">AAN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319204-new-tax-rule-benefit-aarons-and-rent-center\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New tax rule could benefit Aaron&#39;s and Rent-A-Center</a></h4><ul>     <li>Aaron's (<a href='https://seekingalpha.com/symbol/AAN' title='Aaron&#39;s Inc.'>AAN</a> <font color='green'>+6%</font>) rallies after the retailer is singled out by Stifel Nicolaus as a company that is positioned to benefit from the proposed tax reform package.</li>     <li>Analyst John Baugh points to the deduction of capital expenditures. \"Everyone is focusing on the change in the corporate tax rate, which looks like it will get reduced from 35% to 21%, but our lease-to-own companies, like Aaron&rsquo;s and Rent-A-Center, receive another benefit from the ability to fully expense capital purchases,\"&nbsp; he writes,</li><li>\"The ability to immediately deduct inventory purchases would dramatically reduce cash taxes paid in the near term,\" he adds.</li><li>Rent-A-Center (<a href='https://seekingalpha.com/symbol/RCII' title='Rent-A-Center Inc.'>RCII</a> <font color='green'>+0.1%</font>) isn't catching the same kind of buying action as Aaron's today.</li><li>Sources: CNBC and Bloomberg</li> </ul><div class=\"tiny-share-widget\" data-id=\"3319204\" data-linked=\"New tax rule could benefit Aaron&#39;s and Rent-A-Center\" data-tweet=\"$AAN $AAN $RCII - New tax rule could benefit Aaron&#39;s and Rent-A-Center https://seekingalpha.com/news/3319204-new-tax-rule-benefit-aarons-and-rent-center?source=tweet\" data-url=\"https://seekingalpha.com/news/3319204-new-tax-rule-benefit-aarons-and-rent-center\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319203\" data-ts=\"1513706522\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319203-financials-top-5-gainers-losers-of-1-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/RCG' title='RENN Global Entrepreneurs Fund'>RCG</a> <font color='green'>+39%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CCCR-OLD' title='China Commercial Credit'>CCCR-OLD</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/GROW' title='U.S. Global Investors, Inc.'>GROW</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/LMFA' title='LM Funding America, Inc.'>LMFA</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/BLX' title='Banco Latinoamericano De Comercio Exterior, S.A.'>BLX</a> <font color='red'>-6%</font>. PBIB <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3319203\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM\" data-tweet=\"$RCG $CCCR-OLD $GROW - Financials - Top 5 Gainers / Losers as of 1:00 PM https://seekingalpha.com/news/3319203-financials-top-5-gainers-losers-of-1-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3319203-financials-top-5-gainers-losers-of-1-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319200\" data-ts=\"1513706019\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PCTY\" target=\"_blank\">PCTY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319200-dougherty-co-initiates-paylocity\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dougherty &amp; Co. initiates Paylocity</a></h4><ul><li>        Dougherty &amp; Co. <a href=\"http://www.briefing.com/DisplayArticle/ArticlePopup.aspx?ArticleId=IN20171219124302PCTY\" target=\"_blank\">initiates</a> Paylocity (NASDAQ:<a href='https://seekingalpha.com/symbol/PCTY' title='Paylocity Holding Corp'>PCTY</a>) with a Neutral rating. &nbsp;</li><li>        Firm calls Paylocity a SaaS leader that can increase average revenue per client with continued platform and sales expansions.</li><li>               Dougherty expects 22% top-line growth and 13% higher operating margins.&nbsp;</li><li>               But the firm thinks shares are accurately valued at the current 5.9x EV/S on the CY18 estimate. &nbsp;&nbsp;</li><li>               Paylocity shares are&nbsp;<font color='red'>down 2.9%</font>.&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3319200\" data-linked=\"Dougherty &amp; Co. initiates Paylocity\" data-tweet=\"$PCTY - Dougherty &amp; Co. initiates Paylocity https://seekingalpha.com/news/3319200-dougherty-co-initiates-paylocity?source=tweet\" data-url=\"https://seekingalpha.com/news/3319200-dougherty-co-initiates-paylocity\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:53 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319198\" data-ts=\"1513705787\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GKOS\" target=\"_blank\">GKOS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319198-glaukos-on-go-to-start-pivotal-study-of-next-generation-istent-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Glaukos on go to start pivotal study of next-generation iStent; shares up 1%</a></h4><ul><li>The FDA has <a href=\"https://seekingalpha.com/pr/17030030-glaukos-begin-randomized-u-s-ide-pivotal-clinical-trial-istent-sa-system\" target=\"_blank\">signed off</a> on the IDE from Glaukos (<a href='https://seekingalpha.com/symbol/GKOS' title='Glaukos'>GKOS</a> <font color='green'>+1.2%</font>) clearing the way for the launch of a pivotal study of its iStent SA Trabecular Micro-Bypass System to reduce intraocular pressure &#40;IOP&#41;&nbsp;in pseudophakic (no natural crystalline lens), mild-to-moderate primary open-angle, pigmentary or pseudoexfoliative glaucoma patients.</li><li>The iStent SA System consists of two micro-scale titanium stents that are injected into multiple trabecular network locations through a single entry point through the cornea. Once placed, IOP is mitigated by improved fluid drainage from the eye. It has the same fluidic method of action as the original iStent, approved in the U.S. in June 2012.</li></ul><div class=\"tiny-share-widget\" data-id=\"3319198\" data-linked=\"Glaukos on go to start pivotal study of next-generation iStent; shares up 1%\" data-tweet=\"$GKOS - Glaukos on go to start pivotal study of next-generation iStent; shares up 1% https://seekingalpha.com/news/3319198-glaukos-on-go-to-start-pivotal-study-of-next-generation-istent-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3319198-glaukos-on-go-to-start-pivotal-study-of-next-generation-istent-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:49 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319196\" data-ts=\"1513705477\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319196-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/LENS' title='Presbia'>LENS</a> <font color='green'>+128%</font>. <a href='https://seekingalpha.com/symbol/PFNX' title='Pfenex'>PFNX</a> <font color='green'>+64%</font>. <a href='https://seekingalpha.com/symbol/MEET' title='The Meet Group, Inc.'>MEET</a> <font color='green'>+31%</font>. <a href='https://seekingalpha.com/symbol/KONE' title='Kingtone Wirelessinfo Solution Holding Ltd'>KONE</a> <font color='green'>+26%</font>. <a href='https://seekingalpha.com/symbol/CERC' title='Cerecor'>CERC</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/OTIV' title='On Track Innovations Ltd'>OTIV</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/RCG' title='RENN Global Entrepreneurs Fund'>RCG</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/CREG' title='China Recycling Energy Corporation'>CREG</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/MCF' title='Contango Oil & Gas Company'>MCF</a> <font color='green'>+14%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/YTEN' title='Yield10 Bioscience, Inc.'>YTEN</a> <font color='red'>-26%</font>. <a href='https://seekingalpha.com/symbol/NVAX' title='Novavax, Inc.'>NVAX</a> <font color='red'>-22%</font>. <a href='https://seekingalpha.com/symbol/CCCR-OLD' title='China Commercial Credit'>CCCR-OLD</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/ICCC' title='ImmuCell Corporation'>ICCC</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/XNET' title='Xunlei Limited'>XNET</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/BASI' title='Bioanalytical Systems, Inc.'>BASI</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/TRXC' title='TransEnterix, Inc.'>TRXC</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/IPWR' title='Ideal Power Inc.'>IPWR</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/EYES' title='Second Sight Medical Products'>EYES</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/LPTH' title='LightPath Technologies, Inc.'>LPTH</a> <font color='red'>-10%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3319196\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$LENS $PFNX $MEET - Midday Gainers / Losers https://seekingalpha.com/news/3319196-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3319196-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:44 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319194\" data-ts=\"1513704788\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMRX\" target=\"_blank\">AMRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319194-impax-jettisons-taiwan-manufacturing-facility-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Impax jettisons Taiwan manufacturing facility; shares up 1%</a></h4><ul><li>Impax Laboratories (IPXL <font color='green'>+1.3%</font>) inks an <a href=\"https://seekingalpha.com/pr/17030344-impax-announces-sale-taiwan-manufacturing-facility\" target=\"_blank\">agreement </a>to sell its Taiwan-based manufacturing facility to Bora Pharmaceuticals for $18.5M.</li><li>Impax will record a pre-tax impairment charge of $70M - 80M this quarter to account for the loss.</li></ul><div class=\"tiny-share-widget\" data-id=\"3319194\" data-linked=\"Impax jettisons Taiwan manufacturing facility; shares up 1%\" data-tweet=\"$AMRX - Impax jettisons Taiwan manufacturing facility; shares up 1% https://seekingalpha.com/news/3319194-impax-jettisons-taiwan-manufacturing-facility-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3319194-impax-jettisons-taiwan-manufacturing-facility-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:33 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319192\" data-ts=\"1513704232\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CEMI\" target=\"_blank\">CEMI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319192-chembio-teams-up-astrazeneca-to-develop-new-biomarker-test-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chembio teams up with AstraZeneca to develop new biomarker test; shares up 1%</a></h4><ul><li>Chembio Diagnostics (<a href='https://seekingalpha.com/symbol/CEMI' title='Chembio Diagnostics, Inc.'>CEMI</a> <font color='green'>+0.7%</font>) will <a href=\"https://seekingalpha.com/pr/17030350-chembio-diagnostics-astrazeneca-enter-collaboration-develop-point-care-diagnostic-test\" target=\"_blank\">collaborate </a>with AstraZeneca on the development of a novel quantitative point-of-care diagnostic test for an undisclosed biomarker.</li><li>Under the terms of the 18-month agreement, Chembio will receive up to $2.9M from AstraZeneca to support the effort. The test will be performed on Chembio's DPP System.</li></ul><div class=\"tiny-share-widget\" data-id=\"3319192\" data-linked=\"Chembio teams up with AstraZeneca to develop new biomarker test; shares up 1%\" data-tweet=\"$CEMI - Chembio teams up with AstraZeneca to develop new biomarker test; shares up 1% https://seekingalpha.com/news/3319192-chembio-teams-up-astrazeneca-to-develop-new-biomarker-test-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3319192-chembio-teams-up-astrazeneca-to-develop-new-biomarker-test-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319188\" data-ts=\"1513703690\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SVON\" target=\"_blank\">SVON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319188-sevion-to-reverse-split-shares-1-20-after-close-shares-down-11\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sevion to reverse split shares 1:20 after the close; shares down 11%</a></h4><ul><li>Sevion Therapeutics (<a href='https://seekingalpha.com/symbol/SVON' title='Sevion Therapeutics, Inc.'>OTCQB:SVON</a> <font color='red'>-11.4%</font>) will execute a <a href=\"https://seekingalpha.com/pr/17030440-sevion-therapeutics-announces-1minus-20-reverse-stock-split\" target=\"_blank\">1:20 reverse split </a>of its common shares effective at 4:00 pm ET today. Post-split trading will commence tomorrow.</li></ul><div class=\"tiny-share-widget\" data-id=\"3319188\" data-linked=\"Sevion to reverse split shares 1:20 after the close; shares down 11%\" data-tweet=\"$SVON - Sevion to reverse split shares 1:20 after the close; shares down 11% https://seekingalpha.com/news/3319188-sevion-to-reverse-split-shares-1-20-after-close-shares-down-11?source=tweet\" data-url=\"https://seekingalpha.com/news/3319188-sevion-to-reverse-split-shares-1-20-after-close-shares-down-11\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319185\" data-ts=\"1513703503\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OVID\" target=\"_blank\">OVID</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319185-ovids-lead-candidate-fast-trackd-for-rare-neuro-genetic-disorder-shares-ahead-5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ovid&#39;s lead candidate Fast Track&#39;d for rare neuro-genetic disorder; shares ahead 5%</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/17030205-ovid-therapeutics-announces-ov101-granted-fast-track-designation-u-s-fda-treatment-angelman\" target=\"_blank\">designates </a>Ovid Therapeutics' (<a href='https://seekingalpha.com/symbol/OVID' title='Ovid Therapeutics Inc.'>OVID</a> <font color='green'>+4.7%</font>) lead candidate, OV101, for Fast Track review for the treatment of <a href=\"https://www.angelman.org/\" target=\"_blank\">Angelman syndrome</a>, a rare genetic disorder often misdiagnosed as cerebral palsy or autism.</li><li>Angelman patients were recently added to the company's Phase 2 STARS study. Topline data should be available in H2 2018.</li><li>Fast Track status provides for more frequent interaction with the FDA review team and a rolling review of the marketing application.</li><li><a href=\"http://www.ovidrx.com/our-pipeline/\" target=\"_blank\">OV101</a> (gaboxadol) is a delta (&delta;)-selective GABAA receptor agonist designed to specifically target the disruption of tonic inhibition, a central physiological process of the brain that is believed to be the cause of certain neurodevelopmental disorders.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3314895-ovid-include-adolescents-mid-stage-study-lead-candidate-ov101-angelman-syndrome\" target=\"_blank\">Ovid to include adolescents in mid-stage study of lead candidate OV101 in Angelman syndrome</a> (Nov. 28)</li></ul><div class=\"tiny-share-widget\" data-id=\"3319185\" data-linked=\"Ovid&#39;s lead candidate Fast Track&#39;d for rare neuro-genetic disorder; shares ahead 5%\" data-tweet=\"$OVID - Ovid&#39;s lead candidate Fast Track&#39;d for rare neuro-genetic disorder; shares ahead 5% https://seekingalpha.com/news/3319185-ovids-lead-candidate-fast-trackd-for-rare-neuro-genetic-disorder-shares-ahead-5?source=tweet\" data-url=\"https://seekingalpha.com/news/3319185-ovids-lead-candidate-fast-trackd-for-rare-neuro-genetic-disorder-shares-ahead-5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:11 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319184\" data-ts=\"1513702912\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319184-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/OTIV' title='On Track Innovations Ltd'>OTIV</a> <font color='green'>+22%</font>. <a href='https://seekingalpha.com/symbol/FTFT' title='Future Fintech Group Inc'>FTFT</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/KODK' title='Eastman Kodak Co.'>KODK</a> <font color='green'>+10%</font>. XNY <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/NAV' title='Navistar International Corporation'>NAV</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ADOM' title='ADOMANI, Inc.'>ADOM</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3319184\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$OTIV $FTFT $KODK - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3319184-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3319184-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319182\" data-ts=\"1513702607\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INSY\" target=\"_blank\">INSY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319182-insys-initiates-mid-stage-study-of-oral-cannabidiol-for-staring-seizures-in-kids-shares-up-8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">INSYS initiates mid-stage study of oral cannabidiol for &quot;staring&quot; seizures in kids; shares up 8%</a></h4><ul><li>INSYS Therapeutics (<a href='https://seekingalpha.com/symbol/INSY' title='Insys Therapeutics, Inc.'>INSY</a> <font color='green'>+7.6%</font>) <a href=\"https://seekingalpha.com/pr/17030223-insys-therapeutics-initiates-phase-2-clinical-trial-cannabidiol-cbd-oral-solution-treatment\" target=\"_blank\">initiates </a>a Phase 2 clinical trial assessing cannabidiol &#40;CBD&#41; oral solution in epileptic children with treatment-resistant absence or \"staring\" seizures, a condition affecting as many as 8% of the 470K American children with epilepsy.</li><li>The open-label dose-finding study, INS011-17-103, should launch in late 2018.</li></ul><div class=\"tiny-share-widget\" data-id=\"3319182\" data-linked=\"INSYS initiates mid-stage study of oral cannabidiol for &quot;staring&quot; seizures in kids; shares up 8%\" data-tweet=\"$INSY $INSYQ - INSYS initiates mid-stage study of oral cannabidiol for &quot;staring&quot; seizures in kids; shares up 8% https://seekingalpha.com/news/3319182-insys-initiates-mid-stage-study-of-oral-cannabidiol-for-staring-seizures-in-kids-shares-up-8?source=tweet\" data-url=\"https://seekingalpha.com/news/3319182-insys-initiates-mid-stage-study-of-oral-cannabidiol-for-staring-seizures-in-kids-shares-up-8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319181\" data-ts=\"1513702481\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FB\" target=\"_blank\">FB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319181-moffettnathanson-outlines-how-facebook-shares-drop-in-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MoffettNathanson outlines how Facebook shares could drop in 2018</a></h4><ul><li>        MoffettNathanson <a href=\"https://www.cnbc.com/2017/12/19/moffettnathanson-5-reasons-why-facebook-shares-may-fall.html\" target=\"_blank\">reiterates</a> its Buy rating and $205 price target for Facebook (NASDAQ:<a href='https://seekingalpha.com/symbol/FB' title='Facebook'>FB</a>) but outlines how shares could fall in 2018. &nbsp;</li><li>        Analyst Michael Nathanson lists five weaknesses that could lead to the drop: uncertainty surrounding video strategy, hitting upper bound on ad load, questionable monetization potential for WhatsApp and Messenger, emerging regulatory risks, and a positive Street view that could change with &ldquo;hiccups&rdquo; in growth or profits.</li><li>Facebook shares are&nbsp;<font color='red'>down 1.1%</font>.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3319168-u-s-says-facebook-fought-cyber-attacks-germany-questions-data-use\" target=\"_blank\">U.S. says Facebook fought off cyber attacks; Germany questions data use</a> (Dec. 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3319181\" data-linked=\"MoffettNathanson outlines how Facebook shares could drop in 2018\" data-tweet=\"$FB - MoffettNathanson outlines how Facebook shares could drop in 2018 https://seekingalpha.com/news/3319181-moffettnathanson-outlines-how-facebook-shares-drop-in-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3319181-moffettnathanson-outlines-how-facebook-shares-drop-in-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319179\" data-ts=\"1513702275\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XIN\" target=\"_blank\">XIN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319179-xinyuan-real-estate-up-8_4-sa-contributor-makes-strong-call\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Xinyuan Real Estate up 8.4% as SA contributor makes strong call</a></h4><ul><li>Xinyuan (<a href='https://seekingalpha.com/symbol/XIN' title='Xinyuan Real Estate Co., Ltd.'>XIN</a> <font color='green'>+8.4%</font>) caught GeoTeam's attention after <a href=\"http://portal.geoinvesting.com/geoarticles/1262/shares_of_nam_tai_property_likely_to_hit_10_usd_per_share_in_september_on_new_buyback_program\" target=\"_blank\">a bullish article </a>on another China real estate play, Nam Tai Property (NYSE:<a href='https://seekingalpha.com/symbol/NTP' title='Nam Tai Property Inc.'>NTP</a>).</li><li>Geo figures the undercovered Xinyuan<a href=\"https://seekingalpha.com/article/4132666-xinyuan-underpriced-real-estate-story-worth-14-added-blockchain-call-option\" target=\"_blank\"> trades at nearly a 60% discount </a>to book value. Meanwhile, shareholder-friendly management has been paying out a steadily increasing dividend, and buying back stock.</li><li>Maybe most exciting given the way markets are behaving of late, investors in Xinyuan are getting a free blockchain call option thanks to the company's partnership with IBM, and an agreement with a subsidiary of 58.com.</li></ul><div class=\"tiny-share-widget\" data-id=\"3319179\" data-linked=\"Xinyuan Real Estate up 8.4% as SA contributor makes strong call\" data-tweet=\"$XIN $XIN $NTP - Xinyuan Real Estate up 8.4% as SA contributor makes strong call https://seekingalpha.com/news/3319179-xinyuan-real-estate-up-8_4-sa-contributor-makes-strong-call?source=tweet\" data-url=\"https://seekingalpha.com/news/3319179-xinyuan-real-estate-up-8_4-sa-contributor-makes-strong-call\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319177\" data-ts=\"1513701966\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EYEG\" target=\"_blank\">EYEG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319177-eyegate-nabs-new-u-s-patent-covering-egpminus-437-shares-ahead-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EyeGate nabs new U.S. patent covering EGP-437; shares ahead 4%</a></h4><ul><li>The USPTO <a href=\"https://seekingalpha.com/pr/17030310-eyegate-awarded-new-u-s-patent-iontophoretic-delivery-corticosteroids-eye\" target=\"_blank\">issues</a> Patent No. 9,820,935 to EyeGate Pharmaceuticals (<a href='https://seekingalpha.com/symbol/EYEG' title='EyeGate Pharmaceuticals'>EYEG</a> <font color='green'>+4.1%</font>) covering the method of delivering corticosteroids through iontophoresis to the eye, the mechanism of action of candidate EGP-437, licensed to Valeant Pharmaceuticals.</li></ul><div class=\"tiny-share-widget\" data-id=\"3319177\" data-linked=\"EyeGate nabs new U.S. patent covering EGP-437; shares ahead 4%\" data-tweet=\"$EYEG - EyeGate nabs new U.S. patent covering EGP-437; shares ahead 4% https://seekingalpha.com/news/3319177-eyegate-nabs-new-u-s-patent-covering-egpminus-437-shares-ahead-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3319177-eyegate-nabs-new-u-s-patent-covering-egpminus-437-shares-ahead-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:46 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319175\" data-ts=\"1513701501\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RIOT\" target=\"_blank\">RIOT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319175-andrew-left-challenges-riot-ceo-to-debate\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Andrew Left challenges Riot CEO to debate</a></h4><ul><li>Citron Research's Andrew Left <a href=\"https://seekingalpha.com/news/3318987-riot-blockchain-soars-40-percent-citron-goes-short\" target=\"_blank\">yesterday announced</a> a short position in Riot Blockchain (NASDAQ:<a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a>), calling the current situation \"full mania.\"</li><li>Today, Left <a href=\"https://twitter.com/CitronResearch/status/943151385532555264\" target=\"_blank\">says Riot is making</a> \"false claims,\" and challenges CEO John O'Rourke to a live debate on CNBC's Fast Money this afternoon.</li><li>RIOT had been flying higher ahead of the latest Left tweet. It's since given back some of those gains, but is still&nbsp;<font color='green'>up 15.5%</font>&nbsp;on the session.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3319155-crypto-co-trade-halted-sec\" target=\"_blank\">Crypto Co. trade halted by SEC</a> (Dec. 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3319175\" data-linked=\"Andrew Left challenges Riot CEO to debate\" data-tweet=\"$RIOT - Andrew Left challenges Riot CEO to debate https://seekingalpha.com/news/3319175-andrew-left-challenges-riot-ceo-to-debate?source=tweet\" data-url=\"https://seekingalpha.com/news/3319175-andrew-left-challenges-riot-ceo-to-debate\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>30&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319173\" data-ts=\"1513701426\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARRY\" target=\"_blank\">ARRY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319173-array-bio-teams-up-pfizer-on-combo-cancer-therapies-shares-up-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Array Bio teams up with Pfizer on combo cancer therapies; shares up 2%</a></h4><ul><li>Array BioPharma (<a href='https://seekingalpha.com/symbol/ARRY' title='Array BioPharma Inc.'>ARRY</a> <font color='green'>+1.8%</font>) and Pfizer (<a href='https://seekingalpha.com/symbol/PFE' title='Pfizer Inc.'>PFE</a> <font color='red'>-0.3%</font>) will <a href=\"https://seekingalpha.com/pr/17030174-array-biopharma-announces-strategic-collaboration-pfizer\" target=\"_blank\">collaborate </a>on clinical trials assessing the safety and efficacy of several immunotherapy combinations to treat cancer. Studies will evaluate the combination of Array's MEK inhibitor binimetinib and Pfizer's PARP inhibitor talazoparib and PD-L1 inhibitor avelumab (being co-developed with Merck KGaA).</li><li>A Phase 1b trial will evaluate doublet and triplet approaches across a range of tumor types with an initial focus on non-small cell lung cancer and pancreatic cancer. The study should commence by Q3 2018.</li><li>Pfizer will sponsor the study while Array will supply product.</li></ul><div class=\"tiny-share-widget\" data-id=\"3319173\" data-linked=\"Array Bio teams up with Pfizer on combo cancer therapies; shares up 2%\" data-tweet=\"$ARRY $ARRY $PFE - Array Bio teams up with Pfizer on combo cancer therapies; shares up 2% https://seekingalpha.com/news/3319173-array-bio-teams-up-pfizer-on-combo-cancer-therapies-shares-up-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3319173-array-bio-teams-up-pfizer-on-combo-cancer-therapies-shares-up-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319172\" data-ts=\"1513700520\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ONCE\" target=\"_blank\">ONCE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319172-fda-oks-sparks-luxturna-for-inherited-retinal-disease-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs Spark&#39;s Luxturna for inherited retinal disease; shares up 1%</a></h4><ul><li>As expected, the FDA <a href=\"https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm589467.htm\" target=\"_blank\">approves </a>Spark Therapeutics' (<a href='https://seekingalpha.com/symbol/ONCE' title='Spark Therapeutics'>ONCE</a> <font color='green'>+1.4%</font>) gene therapy LUXTURNA (voretigene neparvovec) for the treatment of patients with biallelic RPE65-mutation-associated retinal dystrophy.</li><li>An advisory committee unanimously backed approval in October.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3300746-ad-com-backs-sparks-luxturna-gene-therapy-type-retinal-dystrophy\" target=\"_blank\">Ad Com backs Spark's Luxturna gene therapy for type of retinal dystrophy</a> (Oct. 12)</li></ul><div class=\"tiny-share-widget\" data-id=\"3319172\" data-linked=\"FDA OKs Spark&#39;s Luxturna for inherited retinal disease; shares up 1%\" data-tweet=\"$ONCE - FDA OKs Spark&#39;s Luxturna for inherited retinal disease; shares up 1% https://seekingalpha.com/news/3319172-fda-oks-sparks-luxturna-for-inherited-retinal-disease-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3319172-fda-oks-sparks-luxturna-for-inherited-retinal-disease-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319169\" data-ts=\"1513700025\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZBH\" target=\"_blank\">ZBH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319169-new-chief-zimmer-biomet-shares-up-6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New chief at Zimmer Biomet; shares up 6%</a></h4><ul><li>Zimmer Biomet Holdings (<a href='https://seekingalpha.com/symbol/ZBH' title='Zimmer Biomet Holdings, Inc.'>ZBH</a> <font color='green'>+6.3%</font>) <a href=\"https://seekingalpha.com/pr/17030324-zimmer-biomet-announces-appointment-bryan-c-hanson-president-chief-executive-officer\" target=\"_blank\">appoints </a>Bryan Hanson as President &amp; CEO effective today. Interim CEO Daniel Florin will continue to serve as SVP and CFO.</li><li>Previously, Mr. Hanson was EVP and President of the Minimally Invasive Therapies Group at Medtronic.</li></ul><div class=\"tiny-share-widget\" data-id=\"3319169\" data-linked=\"New chief at Zimmer Biomet; shares up 6%\" data-tweet=\"$ZBH - New chief at Zimmer Biomet; shares up 6% https://seekingalpha.com/news/3319169-new-chief-zimmer-biomet-shares-up-6?source=tweet\" data-url=\"https://seekingalpha.com/news/3319169-new-chief-zimmer-biomet-shares-up-6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:13 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319168\" data-ts=\"1513699953\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FB\" target=\"_blank\">FB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319168-u-s-says-facebook-fought-off-cyber-attacks-germany-questions-data-use\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">U.S. says Facebook fought off cyber attacks; Germany questions data use</a></h4><ul><li>        The U.S. homeland security adviser <a href=\"https://www.reuters.com/article/us-usa-cyber-northkorea/u-s-says-facebook-microsoft-disabled-north-korean-cyber-actions-idUSKBN1ED1UE\" target=\"_blank\">says</a> Facebook (NASDAQ:<a href='https://seekingalpha.com/symbol/FB' title='Facebook'>FB</a>) and Microsoft (NASDAQ:<a href='https://seekingalpha.com/symbol/MSFT' title='Microsoft Corporation'>MSFT</a>) disabled North Korean cyber actions last week.</li><li>               Tom Bossert didn&rsquo;t provide additional details but urged other companies to participate in cyber security defense.&nbsp;</li><li>               In Germany, an <a href=\"https://www.reuters.com/article/us-facebook-germany-dataprotection/facebook-abused-dominant-position-says-german-watchdog-idUSKBN1ED10J\" target=\"_blank\">antitrust watchdog says</a> Facebook abused its position by monetizing the personal data of users. Facebook denies the charges.&nbsp;</li><li>               The comments come after the Federal Cartel Office finished a 20-month probe into the company. The authority questioned Facebook&rsquo;s requirement to access third-party data when a user opens an account and how the social network tracks users across different websites.&nbsp;&nbsp;&nbsp;</li><li>Facebook shares are&nbsp;<font color='red'>down 1.3%</font>.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3318982-whatsapp-face-fine-data-sharing\" target=\"_blank\">WhatsApp could face fine for data sharing</a> (Dec. 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3319168\" data-linked=\"U.S. says Facebook fought off cyber attacks; Germany questions data use\" data-tweet=\"$FB $FB $MSFT - U.S. says Facebook fought off cyber attacks; Germany questions data use https://seekingalpha.com/news/3319168-u-s-says-facebook-fought-off-cyber-attacks-germany-questions-data-use?source=tweet\" data-url=\"https://seekingalpha.com/news/3319168-u-s-says-facebook-fought-off-cyber-attacks-germany-questions-data-use\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319145\" data-ts=\"1513699379\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319145-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/LENS' title='Presbia'>LENS</a> <font color='green'>+136%</font>. <a href='https://seekingalpha.com/symbol/PFNX' title='Pfenex'>PFNX</a> <font color='green'>+55%</font>. <a href='https://seekingalpha.com/symbol/CERC' title='Cerecor'>CERC</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/CANF' title='Can-Fite Biopharma Ltd'>CANF</a> <font color='green'>+15%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/NVAX' title='Novavax, Inc.'>NVAX</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/ICCC' title='ImmuCell Corporation'>ICCC</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/EYES' title='Second Sight Medical Products'>EYES</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/TRXC' title='TransEnterix, Inc.'>TRXC</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/BLPH' title='Bellerophon Therapeutics'>BLPH</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3319145\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$LENS $PFNX $CERC - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3319145-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3319145-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:02 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319164\" data-ts=\"1513699002\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AKER\" target=\"_blank\">AKER</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319164-akers-equity-offering-sinks-shares-down-61\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Akers&#39; equity offering sinks shares, down 61%</a></h4><ul><li>Thinly traded nano cap Akers Biosciences (<a href='https://seekingalpha.com/symbol/AKER' title='Akers Biosciences Inc.'>AKER</a> <font color='red'>-61.4%</font>) slumps on a 23x surge in volume in response to its <a href=\"https://www.sec.gov/Archives/edgar/data/1321834/000149315217014740/form8-k.htm\" target=\"_blank\">$6M public equity offering</a>.</li><li>The offering consists of 15.5M Class A Units at $0.15, each comprised of one share of common stock and one five-year warrant to purchase one share of common at $0.1875, and 3,675 Class B Units at $1,000.</li><li>Each Class B unit consists of one share of Series B Convertible Preferred Stock valued at $1,000 plus one five-year warrant to purchase one share of common at $0.1875. Series B shares are convertible into an aggregate of 24.5M common shares (~6,667 common shares/Series B share) at an undisclosed price.</li><li>Underwriters over-allotment is an additional 6M shares of common stock and warrants to purchase up to 6M shares.</li><li>Closing date is December 21.</li><li>Yesterday's close was $0.395.</li></ul><div class=\"tiny-share-widget\" data-id=\"3319164\" data-linked=\"Akers&#39; equity offering sinks shares, down 61%\" data-tweet=\"$AKER - Akers&#39; equity offering sinks shares, down 61% https://seekingalpha.com/news/3319164-akers-equity-offering-sinks-shares-down-61?source=tweet\" data-url=\"https://seekingalpha.com/news/3319164-akers-equity-offering-sinks-shares-down-61\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319165\" data-ts=\"1513698953\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGCO\" target=\"_blank\">AGCO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319165-agcominus-4-2018-earnings-guidance-misses-consensus\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AGCO -4% as 2018 earnings guidance misses consensus</a></h4><ul>     <li>AGCO (<a href='https://seekingalpha.com/symbol/AGCO' title='AGCO Corporation'>AGCO</a> <font color='red'>-4.1%</font>) tumbles more than 4% as its forecast for 2018 adjusted EPS fails to meet analyst expectations.</li>     <li>At an <a href=\"http://investors.agcocorp.com/phoenix.zhtml?c=108419&amp;p=irol-presentations\" target=\"_blank\">analyst presentation</a> today, AGCO issued guidance for FY 2018 EPS of ~$3.50 vs. $3.83 analyst consensus estimate, as projected 2018 farm income remains under pressure.</li>     <li>However, AGCO's 2018 revenue forecast of $9B exceeds analyst consensus of $8.48B; the company also sees 2017 capex totaling $50M.</li>     <li>AGCO peers Deere (<a href='https://seekingalpha.com/symbol/DE' title='Deere & Company'>DE</a> <font color='red'>-0.3%</font>), Caterpillar (<a href='https://seekingalpha.com/symbol/CAT' title='Caterpillar Inc.'>CAT</a> <font color='red'>-0.5%</font>) and Lindsay (<a href='https://seekingalpha.com/symbol/LNN' title='Lindsay Corporation'>LNN</a> <font color='red'>-0.4%</font>) are modestly lower.</li><li>Source:&nbsp;Bloomberg First Word</li></ul><div class=\"tiny-share-widget\" data-id=\"3319165\" data-linked=\"AGCO -4% as 2018 earnings guidance misses consensus\" data-tweet=\"$AGCO $AGCO $DE - AGCO -4% as 2018 earnings guidance misses consensus https://seekingalpha.com/news/3319165-agcominus-4-2018-earnings-guidance-misses-consensus?source=tweet\" data-url=\"https://seekingalpha.com/news/3319165-agcominus-4-2018-earnings-guidance-misses-consensus\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319161\" data-ts=\"1513698327\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319161-new-leg-higher-in-yields-after-fast-housing-starts-print\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New leg higher in yields after fast housing starts print</a></h4><ul><li><a href=\"https://seekingalpha.com/news/3319115-housing-starts-top-expectations\" target=\"_blank\">Housing starts rose</a> to a seasonally-adjusted annualized rate of 1.297M in November, up 3.3% from October and 12.9% from a year ago. It's also the second-strongest pace since the financial crisis.</li><li>Excluding more volatile multifamily numbers, single-family starts rose 5.3% M/M in November.</li><li>The news has helped send the 10-year Treasury yield up a full five basis points to 2.44%. The yield is now higher by about 40 basis points since Labor Day, and within sight of the 2017 high of 2.62% touched in early March.</li><li><a href='https://seekingalpha.com/symbol/TLT' title='iShares 20+ Year Treasury Bond ETF'>TLT</a>&nbsp;<font color='red'>-1%</font>, <a href='https://seekingalpha.com/symbol/TBT' title='ProShares UltraShort 20+ Year Treasury ETF'>TBT</a>&nbsp;<font color='green'>+2%</font></li><li>ETFs: <a href='https://seekingalpha.com/symbol/TLT' title='iShares 20+ Year Treasury Bond ETF'>TLT</a>, <a href='https://seekingalpha.com/symbol/TBT' title='ProShares UltraShort 20+ Year Treasury ETF'>TBT</a>, <a href='https://seekingalpha.com/symbol/TMV' title='Direxion Daily 20+ Year Treasury Bear 3x Shares ETF'>TMV</a>, <a href='https://seekingalpha.com/symbol/TBF' title='ProShares Short 20+ Year Treasury ETF'>TBF</a>, <a href='https://seekingalpha.com/symbol/EDV' title='Vanguard Extended Duration Treasury ETF'>EDV</a>, <a href='https://seekingalpha.com/symbol/TMF' title='Direxion Daily 30-Year Treasury Bull 3x Shares ETF'>TMF</a>, <a href='https://seekingalpha.com/symbol/TTT' title='ProShares UltraPro Short 20+ Year Treasury ETF'>TTT</a>, <a href='https://seekingalpha.com/symbol/ZROZ' title='PIMCO 25+ Year Zero Coupon U.S. Treasury Index ETF'>ZROZ</a>, <a href='https://seekingalpha.com/symbol/VGLT' title='Vanguard Long-Term Government Bond Index ETF'>VGLT</a>, <a href='https://seekingalpha.com/symbol/TLH' title='iShares 10-20 Year Treasury Bond ETF'>TLH</a>, <a href='https://seekingalpha.com/symbol/UBT' title='ProShares Ultra 20+ Year Treasury ETF'>UBT</a>, <a href='https://seekingalpha.com/symbol/SPTL' title='SPDR Portfolio Long Term Treasury ETF'>SPTL</a>, <a href='https://seekingalpha.com/symbol/DLBS' title='iPath U.S. Treasury Long Bond Bear ETN'>DLBS</a>, <a href='https://seekingalpha.com/symbol/VUSTX' title='Vanguard Long Term Treasury Fund Inv'>VUSTX</a>, <a href='https://seekingalpha.com/symbol/TYBS' title='Direxion Daily 20+ Year Treasury Bear 1x Shares ETF'>TYBS</a>, <a href='https://seekingalpha.com/symbol/DLBL' title='iPath U.S. Treasury Long Bond Bull ETN'>DLBL</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3319161\" data-linked=\"New leg higher in yields after fast housing starts print\" data-tweet=\"$TLT $TBT $TMV - New leg higher in yields after fast housing starts print https://seekingalpha.com/news/3319161-new-leg-higher-in-yields-after-fast-housing-starts-print?source=tweet\" data-url=\"https://seekingalpha.com/news/3319161-new-leg-higher-in-yields-after-fast-housing-starts-print\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319159\" data-ts=\"1513697827\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LENS\" target=\"_blank\">LENS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319159-presbia-up-big-on-heels-of-business-reboot-shares-ahead-150\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Presbia up big on heels of business reboot; shares ahead 150%</a></h4><ul><li>Thinly traded nano cap Presbia (<a href='https://seekingalpha.com/symbol/LENS' title='Presbia'>LENS</a> <font color='green'>+149.6%</font>) is up on a healthy 30x surge in volume, albeit on turnover of only 207K shares. No particular news accounts for today's action.</li><li>Last week, the company announced a realignment of strategic priorities and a cash infusion that should be sufficient to fund operations through next year.</li><li>At the end of Q3, it had <a href=\"https://www.sec.gov/Archives/edgar/data/1591096/000156459017023788/lens-10q_20170930.htm#CONSOLIDATED_STATEMENTS_CASH_FLOWS\" target=\"_blank\">$7M in cash</a> while operations consumed $10.7M during the first nine months of the year.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3318531-presbia-announces-board-management-changes-financing-proposal\" target=\"_blank\">Presbia announces board and management changes and financing proposal</a> (Dec. 15)</li></ul><div class=\"tiny-share-widget\" data-id=\"3319159\" data-linked=\"Presbia up big on heels of business reboot; shares ahead 150%\" data-tweet=\"$LENS - Presbia up big on heels of business reboot; shares ahead 150% https://seekingalpha.com/news/3319159-presbia-up-big-on-heels-of-business-reboot-shares-ahead-150?source=tweet\" data-url=\"https://seekingalpha.com/news/3319159-presbia-up-big-on-heels-of-business-reboot-shares-ahead-150\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:37 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319158\" data-ts=\"1513697514\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CCL\" target=\"_blank\">CCL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319158-carnival-rides-out-hurricanes-better-anticipated\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Carnival rides out hurricanes better than anticipated</a></h4><ul> <li>Carnival (<a href='https://seekingalpha.com/symbol/CCL' title='Carnival Corporation'>CCL</a> <font color='green'>+2.4%</font>) trades higher after topping estimates comfortably with its FQ4 report.</li> <li>The company's gross revenue yield growth of 6.8% per available lower berth day was outpaced by a 9.7% increase in gross cruise costs per ALBD.</li> <li>The disruptions from hurricanes shaved about $0.11 off of EPS during the quarter.</li> <li>\"Despite booking disruptions from this year's multiple hurricanes, we are still heading into 2018 with a stronger base of business and higher prices than last year,\" says Carnival CEO Arnold Donald.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3319158\" data-linked=\"Carnival rides out hurricanes better than anticipated\" data-tweet=\"$CCL - Carnival rides out hurricanes better than anticipated https://seekingalpha.com/news/3319158-carnival-rides-out-hurricanes-better-anticipated?source=tweet\" data-url=\"https://seekingalpha.com/news/3319158-carnival-rides-out-hurricanes-better-anticipated\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319155\" data-ts=\"1513696743\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRCW\" target=\"_blank\">CRCW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319155-crypto-co-trade-halted-sec\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Crypto Co. trade halted by SEC</a></h4><ul><li>Citing concern on the accuracy and adequacy of information in the marketplace, the <a href=\"https://www.marketwatch.com/story/sec-suspends-trade-in-crypto-co-shares-after-meteoric-rise-in-recent-trade-2017-12-19?siteid=yhoof2&amp;yptr=yahoo\" target=\"_blank\">SEC has suspended</a> trading Crypto Co (<a href='https://seekingalpha.com/symbol/CRCW' title='The Crypto Company'>OTC:CRCW</a>). The suspension is to stay in place through January 3.</li><li>The thinly traded stock - backed by a company with very little in the way of assets or income - exploded to as high as a $12B valuation earlier this month.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3318067-bitcoin-mania-seen-stock\" target=\"_blank\">Bitcoin mania as seen in a stock</a> (Dec. 13)</li><li>Checking other blockchain-related absurdities, Longfin (<a href='https://seekingalpha.com/symbol/LFIN' title='LongFin Corp.A'>OTCPK:LFIN</a>) is&nbsp;<font color='red'>down a mere 8.5%</font>&nbsp;today to $66.15, and now&nbsp;<font color='red'>off 50%&nbsp;</font>from yesterday's peak. The recently-IPO'd fintech company sports just shy of a $4B valuation.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3318939-longfin-rocketship-still-going\" target=\"_blank\">Longfin rocketship still going</a> (Dec. 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3319155\" data-linked=\"Crypto Co. trade halted by SEC\" data-tweet=\"$CRCW $CRCW $LFIN - Crypto Co. trade halted by SEC https://seekingalpha.com/news/3319155-crypto-co-trade-halted-sec?source=tweet\" data-url=\"https://seekingalpha.com/news/3319155-crypto-co-trade-halted-sec\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>33&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319144\" data-ts=\"1513695271\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLVS\" target=\"_blank\">CLVS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319144-ema-requests-additional-input-on-clovis-marketing-application-for-rucaparib-shares-down-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EMA requests additional input on Clovis&#39; marketing application for rucaparib; shares down 1%</a></h4><ul><li>The European Medicines Agency's Committee for Medicinal Products for Human Use &#40;CHMP&#41; has <a href=\"https://seekingalpha.com/pr/17030161-rucaparib-maa-ovarian-cancer-treatment-indication-referred-chmp-scientific-advisory-group\" target=\"_blank\">requested </a>an opinion from the Scientific Advisory Group &#40;SAG&#41; on Oncology on certain technical aspects of Clovis Oncology's (<a href='https://seekingalpha.com/symbol/CLVS' title='Clovis Oncology'>CLVS</a> <font color='red'>-0.7%</font>) marketing application for the potential conditional approval of rucaparib in treatment-resistant ovarian cancer. The application was filed about a year ago.</li><li>The company expects the scientific advisory group to meet sometime in early February 2018.</li><li>It also plans to initiate a new marketing application for rucaparib as maintenance treatment for ovarian cancer next month. The filing will be made as an amendment to its current application if approved by Q2.</li></ul><div class=\"tiny-share-widget\" data-id=\"3319144\" data-linked=\"EMA requests additional input on Clovis&#39; marketing application for rucaparib; shares down 1%\" data-tweet=\"$CLVS - EMA requests additional input on Clovis&#39; marketing application for rucaparib; shares down 1% https://seekingalpha.com/news/3319144-ema-requests-additional-input-on-clovis-marketing-application-for-rucaparib-shares-down-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3319144-ema-requests-additional-input-on-clovis-marketing-application-for-rucaparib-shares-down-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:54 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319139\" data-ts=\"1513693713\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CGIX\" target=\"_blank\">CGIX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319139-cancer-genetics-up-7-premarket-on-ny-ok-of-lung-cancer-test\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cancer Genetics up 7% premarket on NY OK of lung cancer test</a></h4><ul><li>Thinly traded nano cap Cancer Genetics (NASDAQ:<a href='https://seekingalpha.com/symbol/CGIX' title='Cancer Genetics, Inc.'>CGIX</a>) is up&nbsp;<font color='green'>7%</font>&nbsp;premarket on increased volume on the heels of its <a href=\"https://seekingalpha.com/pr/17030105-cancer-genetics-receives-new-york-state-approval-fda-approved-oncomine-dx-target-test-thermo\" target=\"_blank\">announcement </a>that the New York State Department of Health has approved Thermo Fisher's Oncomine Dx Target Test for lung cancer, a test provided by CGIX.</li></ul><div class=\"tiny-share-widget\" data-id=\"3319139\" data-linked=\"Cancer Genetics up 7% premarket on NY OK of lung cancer test\" data-tweet=\"$CGIX - Cancer Genetics up 7% premarket on NY OK of lung cancer test https://seekingalpha.com/news/3319139-cancer-genetics-up-7-premarket-on-ny-ok-of-lung-cancer-test?source=tweet\" data-url=\"https://seekingalpha.com/news/3319139-cancer-genetics-up-7-premarket-on-ny-ok-of-lung-cancer-test\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:28 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319137\" data-ts=\"1513693336\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PFNX\" target=\"_blank\">PFNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319137-pfenex-amends-deal-jazz-pharma-eligible-for-additional-43_5m-in-milestones-shares-ahead-13\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pfenex amends deal with Jazz Pharma, eligible for additional $43.5M in milestones; shares ahead 13% premarket</a></h4><ul><li>Thinly traded nano cap Pfenex (NYSEMKT:<a href='https://seekingalpha.com/symbol/PFNX' title='Pfenex'>PFNX</a>) is up&nbsp;<font color='green'>13%</font>&nbsp;premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/17030148-pfenex-earns-18_5-million-milestones-updates-worldwide-license-option-agreement-jazz\" target=\"_blank\">announcement </a>that it has amended its 2016 hematology product development agreement with Jazz Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/JAZZ' title='Jazz Pharmaceuticals, Inc.'>JAZZ</a>). Under the terms of the updated agreement, it will be eligible to receive an additional $43.5M in milestones (includes a $5M amendment fee), increasing the total value of all potential payments to $224.5M.</li><li>Pfenex earned $18.5M in Q4 under the partnership, $13.5M in milestones plus the amendment fee.</li></ul><div class=\"tiny-share-widget\" data-id=\"3319137\" data-linked=\"Pfenex amends deal with Jazz Pharma, eligible for additional $43.5M in milestones; shares ahead 13% premarket\" data-tweet=\"$PFNX $PFNX $JAZZ - Pfenex amends deal with Jazz Pharma, eligible for additional $43.5M in milestones; shares ahead 13% premarket https://seekingalpha.com/news/3319137-pfenex-amends-deal-jazz-pharma-eligible-for-additional-43_5m-in-milestones-shares-ahead-13?source=tweet\" data-url=\"https://seekingalpha.com/news/3319137-pfenex-amends-deal-jazz-pharma-eligible-for-additional-43_5m-in-milestones-shares-ahead-13\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319136\" data-ts=\"1513693289\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GM\" target=\"_blank\">GM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319136-gm-seen-long-term-autonomous-play\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GM seen as long-term autonomous play</a></h4><ul> <li>Shares of General Motors (NYSE:<a href='https://seekingalpha.com/symbol/GM' title='General Motors Company'>GM</a>) are making a nice little move in the premarket session after RBC Capital Markets lifts its <a href=\"https://www.cnbc.com/2017/12/19/gm-shares-rise-after-rbc-upgrades-to-outperform.html\" target=\"_blank\">estimates</a>&nbsp;for the automaker's 2018 profit and upgrades to Outperform.</li> <li>\"The stock fits squarely into our preferred narrative for 2018 &ndash; increased confidence on downturn resiliency with a seat at the table on new mobility,\" writes analyst Joseph Spak.</li> <li>Spak also likes GM for the long term as an autonomous vehicle industry play.</li> <li>\"We believe autonomous will first permeate in urban areas where the cost/mile is very high which is likely why GM is testing in those locations. Interestingly, GM is typically under-represented in urban areas so the cannibalization of itself is lower and shared autonomous looks to be an incremental opportunity for GM,\" he observes.</li> <li>GM <font color='green'>+1.34%</font> premarket to $42.70.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3319136\" data-linked=\"GM seen as long-term autonomous play\" data-tweet=\"$GM - GM seen as long-term autonomous play https://seekingalpha.com/news/3319136-gm-seen-long-term-autonomous-play?source=tweet\" data-url=\"https://seekingalpha.com/news/3319136-gm-seen-long-term-autonomous-play\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319135\" data-ts=\"1513693117\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319135-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/CREG' title='China Recycling Energy Corporation'>CREG</a> <font color='green'>+57%</font>&nbsp;signed a <a href=\"https://seekingalpha.com/pr/17030219-china-recycling-energy-announces-energy-storage-development-cooperation-contract-shanghai\" target=\"_blank\">contract</a> with Shanghai Electric Distributed Energy Sources Technology.</li>     <li><a href='https://seekingalpha.com/symbol/NXTD' title='NXT-ID Inc.'>NXTD</a> <font color='green'>+21%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/17030106-anz-nxt-id-subsidiary-fit-pay-collaborate-bring-new-tap-go-payment-devices-australian-market\" target=\"_blank\">agreement</a> to extend contactless payment capabilities to a range of new devices.</li>     <li><a href='https://seekingalpha.com/symbol/OTIV' title='On Track Innovations Ltd'>OTIV</a> <font color='green'>+16%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/TEUM' title='Pareteum Corporation'>TEUM</a> <font color='green'>+15%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/17030185-pareteum-eliminates-atalaya-senior-secured-debt\" target=\"_blank\">eliminating</a> Atalaya senior secured debt.</li>     <li><a href='https://seekingalpha.com/symbol/MEET' title='The Meet Group, Inc.'>MEET</a> <font color='green'>+13%</font>&nbsp;on preliminary Q4, FY17 <a href=\"https://seekingalpha.com/news/3319111\" target=\"_blank\">results</a>.</li>     <li><a href='https://seekingalpha.com/symbol/AMPE' title='Ampio Pharmaceuticals, Inc.'>AMPE</a> <font color='green'>+10%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/NAV' title='Navistar International Corporation'>NAV</a> <font color='green'>+10%</font>&nbsp;on Q4&nbsp;<a href=\"https://seekingalpha.com/news/3319068-navistar-eps-1_36\" target=\"_blank\">result</a>.</li>     <li><a href='https://seekingalpha.com/symbol/CARS' title='Cars.com Inc.'>CARS</a> <font color='green'>+9%</font>&nbsp;on Starboard 9.9% active stake <a href=\"https://seekingalpha.com/news/3319042-cars-com-plus-8-percent-starboard-9_9-percent-active-stake-disclosure\" target=\"_blank\">disclosure</a>.</li>     <li><a href='https://seekingalpha.com/symbol/CGIX' title='Cancer Genetics, Inc.'>CGIX</a> <font color='green'>+8%</font>&nbsp;on FDA <a href=\"https://seekingalpha.com/pr/17030105-cancer-genetics-receives-new-york-state-approval-fda-approved-oncomine-dx-target-test-thermo\" target=\"_blank\">approval</a>&nbsp;for Thermo Fisher Scientific&rsquo;s Oncomine Dx Target Test.</li>     <li>CLNT <font color='green'>+6%</font>&nbsp;as&nbsp;<a href=\"https://seekingalpha.com/news/3319131-cleantech-enters-coworking-space-business-deal-anyworkspace\" target=\"_blank\">enters</a> coworking space business with deal for AnyWorkspace.</li>     <li><a href='https://seekingalpha.com/symbol/BASI' title='Bioanalytical Systems, Inc.'>BASI</a> <font color='green'>+6%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/ARRY' title='Array BioPharma Inc.'>ARRY</a> <font color='green'>+5%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/17030174-array-biopharma-announces-strategic-collaboration-pfizer\" target=\"_blank\">entering</a> into a clinical trial collaboration agreement with Pfizer.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3319135\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$CREG $NXTD $OTIV - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3319135-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3319135-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319134\" data-ts=\"1513693034\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CCL\" target=\"_blank\">CCL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319134-carnival-beats-0_12-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Carnival beats by $0.12, beats on revenue</a></h4><ul><li>Carnival (NYSE:<a href='https://seekingalpha.com/symbol/CCL' title='Carnival Corporation'>CCL</a>): Q4 EPS of $0.63 <font color='green'>beats by $0.12</font>.</li><li>Revenue of $4.26B (+8.1% Y/Y) <font color='green'>beats by $110M</font>.</li><li>Shares <font color='green'>+1.92%</font> PM.</li><li><a href=\"https://seekingalpha.com/pr/17030498-carnival-corporation-and-plc-reports-full-year-fourth-quarter-earnings\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3319134\" data-linked=\"Carnival beats by $0.12, beats on revenue\" data-tweet=\"$CCL $CUK $CUKPF - Carnival beats by $0.12, beats on revenue https://seekingalpha.com/news/3319134-carnival-beats-0_12-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3319134-carnival-beats-0_12-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319133\" data-ts=\"1513693028\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319133-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/LFIN' title='LongFin Corp.A'>OTCPK:LFIN</a>&nbsp;<font color='red'>-26%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3319087-south-korean-crypto-exchange-collapses-btc-slides-18k\" target=\"_blank\">collapse</a> of South Korean crypto exchange.</li><li><a href='https://seekingalpha.com/symbol/YTEN' title='Yield10 Bioscience, Inc.'>YTEN</a> <font color='red'>-25%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/17030338-yield10-bioscience-announces-pricing-12_6-million-public-offering\" target=\"_blank\">pricing</a> $12.6M public offering.</li><li><a href='https://seekingalpha.com/symbol/NVAX' title='Novavax, Inc.'>NVAX</a>&nbsp;<font color='red'>-16%</font>&nbsp;on investors being <a href=\"https://seekingalpha.com/news/3319030-novavax-accelerates-enrollment-late-stage-study-rsv-vaccine-interim-data-expected-midminus\" target=\"_blank\">disappointed</a> with the timing of Phase 1/2 data for NanoFlu.</li><li><a href='https://seekingalpha.com/symbol/MARA' title='Marathon Patent Group, Inc.'>MARA</a>&nbsp;<font color='red'>-12%</font>&nbsp;on&nbsp;<a href=\"https://seekingalpha.com/news/3319087-south-korean-crypto-exchange-collapses-btc-slides-18k\" target=\"_blank\">collapse</a>&nbsp;of South Korean crypto exchange.</li><li><a href='https://seekingalpha.com/symbol/DPW' title='DPW Holdings, Inc.'>DPW</a>&nbsp;<font color='red'>-9%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3319028-digital-power-files-mixed-shelf\" target=\"_blank\">filing</a> for mixed shelf.</li><li><a href='https://seekingalpha.com/symbol/SIEB' title='Siebert Financial Corp.'>SIEB</a> <font color='red'>-9%</font>.</li><li><a href='https://seekingalpha.com/symbol/GROW' title='U.S. Global Investors, Inc.'>GROW</a>&nbsp;<font color='red'>-7%</font>&nbsp;on&nbsp;<a href=\"https://seekingalpha.com/news/3319087-south-korean-crypto-exchange-collapses-btc-slides-18k\" target=\"_blank\">collapse</a>&nbsp;of South Korean crypto exchange.</li><li><a href='https://seekingalpha.com/symbol/SRAX' title='Social Reality Inc.'>SRAX</a>&nbsp;<font color='red'>-7%</font>&nbsp;on&nbsp;<a href=\"https://seekingalpha.com/news/3319087-south-korean-crypto-exchange-collapses-btc-slides-18k\" target=\"_blank\">collapse</a>&nbsp;of South Korean crypto exchange.</li><li><a href='https://seekingalpha.com/symbol/KND' title='Kindred Healthcare, Inc.'>KND</a>&nbsp;<font color='red'>-5%</font>&nbsp;on being <a href=\"https://seekingalpha.com/news/3319117-kindred-acquired-three-group-consortium-9-per-share\" target=\"_blank\">acquired</a> by three-group consortium for $9 per share.</li><li><a href='https://seekingalpha.com/symbol/DSS' title='Document Security Systems, Inc'>DSS</a> <font color='red'>-5%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3319133\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$LFIN $YTEN $NVAX - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3319133-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3319133-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319131\" data-ts=\"1513692685\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SEII\" target=\"_blank\">SEII</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319131-cleantech-enters-coworking-space-business-deal-for-anyworkspace\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cleantech enters coworking space business with deal for AnyWorkspace</a></h4><ul>     <li>Cleantech Solutions (CLNT)&nbsp;<font color='green'>+6.5%</font> premarket after <a href=\"https://seekingalpha.com/pr/17030005-cleantech-solutions-international-enters-share-purchase-agreement-anyworkspace-expand\" target=\"_blank\">agreeing to acquire</a> 80% of Hong Kong-based AnyWorkspace for $560K in stock to expand into the coworking space.</li><li>AnyWorkspace \"enables both corporate  and individual clients to look for suitable places to work,\"  says CLNT&nbsp;COO Parkson Yip. \"The AnyWorkspace platform  connects space providers and space users in a convenient way and at a  low cost.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3319131\" data-linked=\"Cleantech enters coworking space business with deal for AnyWorkspace\" data-tweet=\"$SEII - Cleantech enters coworking space business with deal for AnyWorkspace https://seekingalpha.com/news/3319131-cleantech-enters-coworking-space-business-deal-for-anyworkspace?source=tweet\" data-url=\"https://seekingalpha.com/news/3319131-cleantech-enters-coworking-space-business-deal-for-anyworkspace\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:11 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319129\" data-ts=\"1513692260\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MARK\" target=\"_blank\">MARK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319129-remark-holdings-announces-4m-kankan-agreement\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Remark Holdings announces $4M KanKan agreement</a></h4><ul><li>        Remark Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/MARK' title='Remark Holdings, Inc.'>MARK</a>) announces a <a href=\"http://ir.remarkholdings.com/releasedetail.cfm?ReleaseID=1052208\" target=\"_blank\">new agreement</a> with the Bank of China related to Remark&rsquo;s KanKan fintech product.</li><li>               The bank will use KanKan for a new consumer loan product after previously using the AI-based system to find customers less likely to default on loans.&nbsp;</li><li>               Remark expects the new contract to generate over $4M in revenue during 2018.&nbsp;</li><li>Remark shares are&nbsp;<font color='green'>up 2.1%</font>&nbsp;premarket.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3318873-remark-plus-13_7-percent-cp-group-investment\" target=\"_blank\">Remark +13.7% after CP Group investment</a> (Dec. 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3319129\" data-linked=\"Remark Holdings announces $4M KanKan agreement\" data-tweet=\"$MARK - Remark Holdings announces $4M KanKan agreement https://seekingalpha.com/news/3319129-remark-holdings-announces-4m-kankan-agreement?source=tweet\" data-url=\"https://seekingalpha.com/news/3319129-remark-holdings-announces-4m-kankan-agreement\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319124\" data-ts=\"1513691793\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SCMP\" target=\"_blank\">SCMP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319124-premarket-analyst-action-healthcare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket analyst action - healthcare</a></h4><ul><li>Sucampo Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/SCMP' title='Sucampo Pharmaceuticals, Inc.'>SCMP</a>) initiated with Buy rating and $43 (157% upside) price target by Nomura Securities. Shares up&nbsp;<font color='green'>4%</font>&nbsp;premarket on light volume.</li><li>Akebia Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AKBA' title='Akebia Therapeutics, Inc.'>AKBA</a>) initiated with Overweight rating and $26 (70% upside) price target by Piper Jaffray. Shares are up&nbsp;<font color='green'>3%</font>&nbsp;premarket on light volume.</li><li>Novavax (NASDAQ:<a href='https://seekingalpha.com/symbol/NVAX' title='Novavax, Inc.'>NVAX</a>) downgraded to Neutral by Citigroup. Shares are down&nbsp;<font color='red'>18%&nbsp;</font>premarket on robust volume as investors appear disappointed with the timing of Phase 1/2 data for NanoFlu.</li></ul><div class=\"tiny-share-widget\" data-id=\"3319124\" data-linked=\"Premarket analyst action - healthcare\" data-tweet=\"$SCMP $SCMP $AKBA - Premarket analyst action - healthcare https://seekingalpha.com/news/3319124-premarket-analyst-action-healthcare?source=tweet\" data-url=\"https://seekingalpha.com/news/3319124-premarket-analyst-action-healthcare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319117\" data-ts=\"1513690884\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KND\" target=\"_blank\">KND</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319117-kindred-to-be-acquired-three-group-consortium-for-9-per-share\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kindred to be acquired by three-group consortium for $9 per share</a></h4><ul><li>Kindred Healthcare (NYSE:<a href='https://seekingalpha.com/symbol/KND' title='Kindred Healthcare, Inc.'>KND</a>) has agreed to be <a href=\"https://seekingalpha.com/pr/17030253-kindred-healthcare-acquired-tpg-capital-welsh-carson-anderson-and-stowe-humana-inc-9_00-per\" target=\"_blank\">acquired </a>by Humana (NYSE:<a href='https://seekingalpha.com/symbol/HUM' title='Humana Inc.'>HUM</a>) and two private equity firms, TPG Capital and Welsh, Carson, Anderson &amp; Stowe, for ~$4.1B in cash ($9/share).</li><li>Humana will take a 40% stake and will have the option to acquire the remaining 60% over time via a put/call arrangement.</li><li>Kindred's LTAC hospitals, in-patient rehab facilities and contract rehabilitation services businesses will be operated as a separate specialty hospital company owned by the PE firms.</li><li>Yesterday's close was $9.50. Shares are down&nbsp;<font color='red'>5%&nbsp;</font>premarket on increased volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3319117\" data-linked=\"Kindred to be acquired by three-group consortium for $9 per share\" data-tweet=\"$KND $KND $HUM - Kindred to be acquired by three-group consortium for $9 per share https://seekingalpha.com/news/3319117-kindred-to-be-acquired-three-group-consortium-for-9-per-share?source=tweet\" data-url=\"https://seekingalpha.com/news/3319117-kindred-to-be-acquired-three-group-consortium-for-9-per-share\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319118\" data-ts=\"1513690578\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACN\" target=\"_blank\">ACN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319118-accenture-announces-minority-investment-in-industrial-tech-company\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Accenture announces minority investment in industrial tech company</a></h4><ul><li>        Accenture (NYSE:<a href='https://seekingalpha.com/symbol/ACN' title='Accenture plc'>ACN</a>) <a href=\"https://seekingalpha.com/pr/17030029-accenture-forms-alliance-maana-help-oil-gas-client-accelerate-digital-transformation\" target=\"_blank\">announces</a> a minority investment in industrial digital transformation company Maana.</li><li>               The two will form a strategic alliance to initially target oil and gas clients with other industries to follow.&nbsp;</li><li>               The alliance will combine Maana&rsquo;s AI-backed knowledge platform for model creation with Accenture&rsquo;s intelligent industry solutions including Digital Plant Operations and Intelligent Operations Center.&nbsp;</li><li>               Terms not disclosed.&nbsp;</li><li>               Accenture shares are&nbsp;<font color='green'>up 0.4%</font>&nbsp;premarket.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3318243-accenture-acquires-irish-creative-agency\" target=\"_blank\">Accenture acquires Irish creative agency</a> (Dec. 14)</li></ul><div class=\"tiny-share-widget\" data-id=\"3319118\" data-linked=\"Accenture announces minority investment in industrial tech company\" data-tweet=\"$ACN - Accenture announces minority investment in industrial tech company https://seekingalpha.com/news/3319118-accenture-announces-minority-investment-in-industrial-tech-company?source=tweet\" data-url=\"https://seekingalpha.com/news/3319118-accenture-announces-minority-investment-in-industrial-tech-company\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319111\" data-ts=\"1513689729\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MEET\" target=\"_blank\">MEET</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319111-meet-groupplus-15_1-on-preliminary-q4-fy17-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">The Meet Group +15.1% on preliminary Q4, FY17 results</a></h4><ul><li>        The Meet Group (NASDAQ:<a href='https://seekingalpha.com/symbol/MEET' title='The Meet Group, Inc.'>MEET</a>) <a href=\"http://ir.themeetgroup.com/file/Index?KeyFile=391503841\" target=\"_blank\">announces</a> preliminary Q4 and FY17 results.</li><li>               Q4 outlook expects revenue to meet or exceed the prior guidance of $36.5M to $38M (consensus: $37.01M) with adjusted EBITDA at the higher end of $7.5M to $9.5M.&nbsp;</li><li>               FY17 guidance has revenue at or above the prior $120.1M to $121.6M (consensus: $120.63M) with adjusted EBIDA at high end of $28.6M to $30.6M.&nbsp;</li><li>               The Meet Group shares are&nbsp;<font color='green'>up 15.1%</font>&nbsp;premarket. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3319111\" data-linked=\"The Meet Group +15.1% on preliminary Q4, FY17 results\" data-tweet=\"$MEET - The Meet Group +15.1% on preliminary Q4, FY17 results https://seekingalpha.com/news/3319111-meet-groupplus-15_1-on-preliminary-q4-fy17-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3319111-meet-groupplus-15_1-on-preliminary-q4-fy17-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319108\" data-ts=\"1513689112\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CREE\" target=\"_blank\">CREE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319108-creeminus-5_7-after-northland-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cree -5.7% after Northland downgrade</a></h4><ul><li>Northland Capital <a href=\"http://www.briefing.com/DisplayArticle/ArticlePopup.aspx?ArticleId=IN20171219071551CREE\" target=\"_blank\">downgrades</a> Cree (NASDAQ:<a href='https://seekingalpha.com/symbol/CREE' title='Cree, Inc.'>CREE</a>) from Market Perform to Underperform with a $28 price target.</li><li>The firm cites pricing pressure in the LED market as a valuation headwind.</li><li>Cree shares are&nbsp;<font color='red'>down 5.7%</font>&nbsp;premarket to $37.32.</li><li>Update:&nbsp;JPMorgan <a href=\"http://www.briefing.com/DisplayArticle/ArticlePopup.aspx?ArticleId=IN20171219074517CREE\" target=\"_blank\">adds</a> Cree (<a href='https://seekingalpha.com/symbol/CREE' title='Cree, Inc.'>CREE</a>) to the Analyst Focus List as a Short Idea.</li><li>The firm reiterates Cree&rsquo;s Underweight rating and $28 price target.</li></ul><div class=\"tiny-share-widget\" data-id=\"3319108\" data-linked=\"Cree -5.7% after Northland downgrade\" data-tweet=\"$CREE - Cree -5.7% after Northland downgrade https://seekingalpha.com/news/3319108-creeminus-5_7-after-northland-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3319108-creeminus-5_7-after-northland-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:11 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319107\" data-ts=\"1513688966\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ULTA\" target=\"_blank\">ULTA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319107-buckingham-sees-breakout-for-ulta-beauty\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Buckingham sees breakout for Ulta Beauty</a></h4><ul> <li>Buckingham Research upgrades Ulta Beauty (NASDAQ:<a href='https://seekingalpha.com/symbol/ULTA' title='Ulta Beauty, Inc.'>ULTA</a>) to a Buy rating from Neutral. \"Beauty is in the eye of the holder,\" <a href=\"https://twitter.com/BuckResearch/status/943104163407450113\" target=\"_blank\">tweets</a> analyst Kelly Crago.</li> <li>The firm hikes its price target on Ulta to $300 from $225 to rep 35% upside potential.</li> <li>ULTA <font color='green'>+0.88%</font> premarket to $224.63.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3319107\" data-linked=\"Buckingham sees breakout for Ulta Beauty\" data-tweet=\"$ULTA - Buckingham sees breakout for Ulta Beauty https://seekingalpha.com/news/3319107-buckingham-sees-breakout-for-ulta-beauty?source=tweet\" data-url=\"https://seekingalpha.com/news/3319107-buckingham-sees-breakout-for-ulta-beauty\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319101\" data-ts=\"1513688440\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAPL\" target=\"_blank\">AAPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319101-nomura-downgrades-apple-lowers-price-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nomura downgrades Apple, lowers price target</a></h4><ul><li>        Nomura Instinet <a href=\"https://www.bloomberg.com/news/articles/2017-12-19/apple-gets-a-rare-downgrade-after-rising-more-than-50-in-2017\" target=\"_blank\">downgrades</a> Apple (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>) from Buy to Neutral and lowers the price target from $185 to $175.</li><li>               Analyst Jeffrey Kvaal says &ldquo;the stock&rsquo;s gains for the iPhone X supercycle are in the late innings&rdquo; and thinks unit growth, if not ASP growth, is baked into the consensus and full multiple.&nbsp;</li><li>               The Nomura action marks Apple&rsquo;s first downgrade since June. &nbsp;&nbsp;</li><li>Apple shares are&nbsp;<font color='red'>down 0.8%</font>&nbsp;premarket.&nbsp; &nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3272896-mizuho-securities-downgrades-apple-shares-nearly-4-percent\" target=\"_blank\">Mizuho Securities downgrades Apple; shares down nearly 4%</a> (June 12)</li></ul><div class=\"tiny-share-widget\" data-id=\"3319101\" data-linked=\"Nomura downgrades Apple, lowers price target\" data-tweet=\"$AAPL - Nomura downgrades Apple, lowers price target https://seekingalpha.com/news/3319101-nomura-downgrades-apple-lowers-price-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3319101-nomura-downgrades-apple-lowers-price-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>148&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319094\" data-ts=\"1513688413\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ONTX\" target=\"_blank\">ONTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319094-onconova-therapeutics-inks-deal-hanx-biopharma-for-on-123300\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Onconova Therapeutics inks deal with HanX Biopharma for ON 123300</a></h4><ul> <li>Onconova Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ONTX' title='Onconova Therapeutics'>ONTX</a>) <a href=\"https://seekingalpha.com/pr/17030102-onconova-therapeutics-announces-license-collaborative-development-agreement-hanx\" target=\"_blank\">signs</a> a license and collaboration agreement with HanX Biopharmaceuticals for the further development and commercialization of ON 123300 in China.</li>  <li>ON 123300 is a dual inhibitor of CDK4/6 + ARK5, which is currently in advanced preclinical development.</li>   <li>Per the agreement, Onconova will receive milestone payments as well as royalties on Chinese sales,&nbsp;retaining global rights outside of China.</li><li>HanX will fund studies&nbsp;towards Investigational New Drug applications in both the US and&nbsp;China.</li><li>Shares are up&nbsp;<font color='green'>16%</font>&nbsp;premarket on light volume.</li>      </ul><div class=\"tiny-share-widget\" data-id=\"3319094\" data-linked=\"Onconova Therapeutics inks deal with HanX Biopharma for ON 123300\" data-tweet=\"$ONTX - Onconova Therapeutics inks deal with HanX Biopharma for ON 123300 https://seekingalpha.com/news/3319094-onconova-therapeutics-inks-deal-hanx-biopharma-for-on-123300?source=tweet\" data-url=\"https://seekingalpha.com/news/3319094-onconova-therapeutics-inks-deal-hanx-biopharma-for-on-123300\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319099\" data-ts=\"1513688306\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KBH\" target=\"_blank\">KBH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319099-kb-homeminus-1_5-jpmorgan-cuts-to-underweight\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">KB Home -1.5% as JPMorgan cuts to Underweight</a></h4><ul><li>More modest performance is on tap for 2018 after a big gains for the homebuilders this year, says JPMorgan's Michael Rehaut. KB Home (NYSE:<a href='https://seekingalpha.com/symbol/KBH' title='KB Home'>KBH</a>) showed particular strength in 2017, doubling vs. the sector's 64% advance.</li><li>Rehuat doesn't think it's industry fundamentals behind this year's big move, but instead money rotating from out-of-favor retail names, and optimism about the tax bill.</li><li>He downgrades KB Home to Underweight, with PulteGroup (NYSE:<a href='https://seekingalpha.com/symbol/PHM' title='PulteGroup, Inc.'>PHM</a>) as his top pick for next year.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3319099\" data-linked=\"KB Home -1.5% as JPMorgan cuts to Underweight\" data-tweet=\"$KBH $KBH $PHM - KB Home -1.5% as JPMorgan cuts to Underweight https://seekingalpha.com/news/3319099-kb-homeminus-1_5-jpmorgan-cuts-to-underweight?source=tweet\" data-url=\"https://seekingalpha.com/news/3319099-kb-homeminus-1_5-jpmorgan-cuts-to-underweight\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:58 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319093\" data-ts=\"1513687840\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MTCH\" target=\"_blank\">MTCH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319093-guggenheim-upgrades-match-group\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Guggenheim upgrades Match Group</a></h4><ul><li>        Guggenheim <a href=\"https://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;source=web&amp;cd=1&amp;cad=rja&amp;uact=8&amp;ved=0ahUKEwjLzLGcjZbYAhUh34MKHXM0CvEQFggnMAA&amp;url=https%3A%2F%2Fwww.streetinsider.com%2FHot%2BUpgrades%2FGuggenheim%2BUpgrades%2BMatch%2BGroup%2B%28MTCH%29%2Bto%2BBuy%2F13613238.html&amp;usg=AOvVaw2YOoTKS3aLmCtWk51Mxaoo\" target=\"_blank\">upgrades</a> Match Group (NASDAQ:<a href='https://seekingalpha.com/symbol/MTCH' title='Match Group, Inc.'>MTCH</a>) from Neutral to Buy with a $40 price target.</li><li>                  Latest analyst <a href=\"https://markets.ft.com/data/equities/tearsheet/forecasts?s=MTCH:NSQ\" target=\"_blank\">recommendations</a>: 6 Buy, 6 Outperform, and 6 Hold. &nbsp;   </li><li>               Median price target: $33. &nbsp;&nbsp;</li><li>                  Match Group shares are&nbsp;<font color='green'>up 3.1%</font>&nbsp;premarket.    &nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3319093\" data-linked=\"Guggenheim upgrades Match Group\" data-tweet=\"$MTCH - Guggenheim upgrades Match Group https://seekingalpha.com/news/3319093-guggenheim-upgrades-match-group?source=tweet\" data-url=\"https://seekingalpha.com/news/3319093-guggenheim-upgrades-match-group\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319091\" data-ts=\"1513687276\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FDS\" target=\"_blank\">FDS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319091-factsetminus-1_8-after-mixed-q1-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FactSet -1.8% after mixed Q1 results</a></h4><ul><li>        FactSet (NYSE:<a href='https://seekingalpha.com/symbol/FDS' title='FactSet Research Systems Inc.'>FDS</a>) reports Q1 earnings with an EPS beat and revenue miss. FY18 guidance has revenue from $1.34B to $1.36B (consensus: $1.35B) and EPS from $8.25 to $8.45 (consensus: $8.19). The company will now only provide FY outlook instead of quarterly.</li><li>               Key metrics: Organic revenue, $304.3M (+5.8% Y/Y); annual subscription value, $1.32B (+$0.15M); organic ASV growth, +5.1%; operating margin, 27.1% (-4.3%); FCF, $55.2M (+$17M); cash from operating activities, $61.1M (+$10M); capital expenditures, $5.9M (-$6.6M).&nbsp;</li><li>               <a href=\"https://seekingalpha.com/pr/17030063-factset-reports-strong-earnings-growth-first-quarter-2018\" target=\"_blank\">Press release</a>&nbsp;</li><li>               FactSet share are&nbsp;<font color='red'>down 1.8%</font>&nbsp;premarket.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3319079-factset-research-systems-beats-0_06-misses-revenue\" target=\"_blank\">FactSet Research Systems beats by $0.06, misses on revenue</a> (Dec. 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3319091\" data-linked=\"FactSet -1.8% after mixed Q1 results\" data-tweet=\"$FDS - FactSet -1.8% after mixed Q1 results https://seekingalpha.com/news/3319091-factsetminus-1_8-after-mixed-q1-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3319091-factsetminus-1_8-after-mixed-q1-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:41 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319088\" data-ts=\"1513686317\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CY\" target=\"_blank\">CY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319088-piper-jaffray-initiates-several-semiconductor-companies\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Piper Jaffray initiates several semiconductor companies</a></h4><ul><li>        Piper Jaffary <a href=\"http://www.briefing.com/DisplayArticle/ArticlePopup.aspx?ArticleId=IN20171218180956MSCC\" target=\"_blank\">initiates</a> coverage on several semiconductor companies.</li><li>        Overweight initiations, with price target: Cypress Semi (NASDAQ:<a href='https://seekingalpha.com/symbol/CY' title='Cypress Semiconductor Corporation'>CY</a>), $20; Microsemi (NASDAQ:<a href='https://seekingalpha.com/symbol/MSCC' title='Microsemi Corporation'>MSCC</a>), $60; Microchip (NASDAQ:<a href='https://seekingalpha.com/symbol/MCHP' title='Microchip Technology Incorporated'>MCHP</a>), $100; Marvell (NASDAQ:<a href='https://seekingalpha.com/symbol/MRVL' title='Marvell Technology Group, Ltd.'>MRVL</a>), $25.</li><li>               Neutral initiations: Semtech (NASDAQ:<a href='https://seekingalpha.com/symbol/SMTC' title='Semtech Corporation'>SMTC</a>), $3; ON Semiconductor (NASDAQ:<a href='https://seekingalpha.com/symbol/ON' title='ON Semiconductor Corporation'>ON</a>), $21; Analog Devices (NASDAQ:<a href='https://seekingalpha.com/symbol/ADI' title='Analog Devices Inc.'>ADI</a>), $92.&nbsp;</li><li>               Cypress Semi shares are&nbsp;<font color='green'>up 1.2%</font>&nbsp;premarket.&nbsp;</li><li>               Microsemi shares are&nbsp;<font color='red'>down 0.3%</font>.&nbsp;</li><li>               Semtech shares are&nbsp;<font color='green'>up 0.3%</font>.&nbsp;</li><li>               ON shares are&nbsp;<font color='green'>up 0.53%</font>. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3319088\" data-linked=\"Piper Jaffray initiates several semiconductor companies\" data-tweet=\"$CY $CY $MSCC - Piper Jaffray initiates several semiconductor companies https://seekingalpha.com/news/3319088-piper-jaffray-initiates-several-semiconductor-companies?source=tweet\" data-url=\"https://seekingalpha.com/news/3319088-piper-jaffray-initiates-several-semiconductor-companies\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319087\" data-ts=\"1513686185\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GBTC\" target=\"_blank\">GBTC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319087-south-korean-crypto-exchange-collapses-btc-slides-under-18k\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">South Korean crypto exchange collapses; BTC slides under $18K</a></h4><ul><li>Seoul-based exchange Youbit<a href=\"https://www.wsj.com/articles/cryptocurrency-exchange-collapses-files-for-bankruptcy-after-second-hack-1513683519\" target=\"_blank\"> suffered its second cyberattack</a> in eight months on Tuesday morning, losing 17% of its total assets. Parent company Yapian suspended trading and filed for bankruptcy.</li><li>Exchange clients were told they were able to withdraw about 75% of their crypto holdings today, with the rest to be returned after bankruptcy proceedings.</li><li>Youbit allowed trading in 10 digital currencies, Bitcoin and Ether among them.</li><li>BTC this morning is&nbsp;<font color='red'>down 5.2%</font>&nbsp;to $17,980. Ether continues its big run,&nbsp;<font color='green'>up 4%&nbsp;</font>to $817.50.</li><li>Related tickers: <a href='https://seekingalpha.com/symbol/GBTC' title='Grayscale Bitcoin Trust &#40;BTC&#41;'>OTCQX:GBTC</a>, <a href='https://seekingalpha.com/symbol/COIN' title='Winklevoss Bitcoin Trust ETF'>COIN</a>, <a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a>, <a href='https://seekingalpha.com/symbol/OSTK' title='Overstock.com, Inc.'>OSTK</a>, <a href='https://seekingalpha.com/symbol/SSC-OLD' title='Seven Stars Cloud Group, Inc.'>SSC-OLD</a>, <a href='https://seekingalpha.com/symbol/MARA' title='Marathon Patent Group, Inc.'>MARA</a>, <a href='https://seekingalpha.com/symbol/UEPS' title='Net 1 UEPS Technologies, Inc.'>UEPS</a>, <a href='https://seekingalpha.com/symbol/BITCF' title='First Bitcoin Capital Corp.'>OTC:BITCF</a>, <a href='https://seekingalpha.com/symbol/XNET' title='Xunlei Limited'>XNET</a>, <a href='https://seekingalpha.com/symbol/GROW' title='U.S. Global Investors, Inc.'>GROW</a>, <a href='https://seekingalpha.com/symbol/BTSC' title='Bitcoin Services, Inc.'>OTCPK:BTSC</a>, <a href='https://seekingalpha.com/symbol/BTCS' title='BTCS Inc.'>OTCQB:BTCS</a>, <a href='https://seekingalpha.com/symbol/MGTI' title='MGT Capital Investments, Inc.'>OTCQB:MGTI</a>, <a href='https://seekingalpha.com/symbol/SRAX' title='Social Reality Inc.'>SRAX</a>, <a href='https://seekingalpha.com/symbol/GAHC' title='Global Arena Holding, Inc.'>OTCPK:GAHC</a>, <a href='https://seekingalpha.com/symbol/UBIA' title='UBI BlockChain Internet Ltd.'>OTC:UBIA</a>, <a href='https://seekingalpha.com/symbol/ARSC' title='American Security Resources Corp.'>OTC:ARSC</a>, <a href='https://seekingalpha.com/symbol/USTC' title='USA Real Estate Holding Co'>OTCPK:USTC</a>, PRELF, <a href='https://seekingalpha.com/symbol/BLKCF' title='Global Blockchain Technologies Corp.'>OTCPK:BLKCF</a>, <a href='https://seekingalpha.com/symbol/CRCW' title='The Crypto Company'>OTC:CRCW</a>, <a href='https://seekingalpha.com/symbol/COINB' title='Coinbase'>COINB</a>, <a href='https://seekingalpha.com/symbol/LFIN' title='LongFin Corp.A'>OTCPK:LFIN</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3319087\" data-linked=\"South Korean crypto exchange collapses; BTC slides under $18K\" data-tweet=\"$GBTC $GBTC $COIN - South Korean crypto exchange collapses; BTC slides under $18K https://seekingalpha.com/news/3319087-south-korean-crypto-exchange-collapses-btc-slides-under-18k?source=tweet\" data-url=\"https://seekingalpha.com/news/3319087-south-korean-crypto-exchange-collapses-btc-slides-under-18k\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>116&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319085\" data-ts=\"1513685987\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DRI\" target=\"_blank\">DRI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319085-store-sales-impress-darden-restaurants\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Same-store sales impress at Darden Restaurants</a></h4><ul> <li>Darden Restaurants (NYSE:<a href='https://seekingalpha.com/symbol/DRI' title='Darden Restaurants, Inc.'>DRI</a>) <a href=\"https://seekingalpha.com/news/3319081-darden-restaurants-beats-0_03-beats-revenue\" target=\"_blank\">reports</a> same-store sales rose 3.1% in FQ2 to sail past the 1.6% mark anticipated by analysts.</li> <li>Same-store sales were up 3.8% for the Lonmghorn Steakhouse chain and 3.0% for Olive Garden during the quarter.</li> <li>Darden ended the quarter with 1,722 company-owned restaurants operating, up from 1,541 a year ago.</li> <li>Looking ahead, Darden expects 2018 EPS of $4.45 to $4.53 vs. $4.38 to $4.50 prior and $4.43 consensus.</li> <li>Shares of Darden are <font color='green'>up 1.61%</font> premarket to $92.10.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3319081-darden-restaurants-beats-0_03-beats-revenue\" target=\"_blank\">Darden Restaurants beats by $0.03, beats on revenue</a> (Dec. 19)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3319085\" data-linked=\"Same-store sales impress at Darden Restaurants\" data-tweet=\"$DRI - Same-store sales impress at Darden Restaurants https://seekingalpha.com/news/3319085-store-sales-impress-darden-restaurants?source=tweet\" data-url=\"https://seekingalpha.com/news/3319085-store-sales-impress-darden-restaurants\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319077\" data-ts=\"1513684840\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDGL\" target=\"_blank\">MDGL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319077-madrigal-prices-stock-offering-83\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Madrigal prices stock offering at $83</a></h4><ul><li>Madrigal Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/MDGL' title='Madrigal Pharmaceuticals, Inc.'>MDGL</a>) <a href=\"https://seekingalpha.com/pr/17029890-madrigal-pharmaceuticals-prices-public-offering-common-stock\" target=\"_blank\">prices </a>its public offering of 1,506,025 shares of common stock at $83 per share. Underwriters over-allotment is an additional 225,904 shares. Closing date is December 21.</li><li>Yesterday's close was $84.04.</li></ul><div class=\"tiny-share-widget\" data-id=\"3319077\" data-linked=\"Madrigal prices stock offering at $83\" data-tweet=\"$MDGL - Madrigal prices stock offering at $83 https://seekingalpha.com/news/3319077-madrigal-prices-stock-offering-83?source=tweet\" data-url=\"https://seekingalpha.com/news/3319077-madrigal-prices-stock-offering-83\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319075\" data-ts=\"1513684675\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ICCC\" target=\"_blank\">ICCC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319075-immucell-prices-stock-offering-7_30\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ImmuCell prices stock offering at $7.30</a></h4><ul><li>ImmuCell (NASDAQ:<a href='https://seekingalpha.com/symbol/ICCC' title='ImmuCell Corporation'>ICCC</a>) <a href=\"https://seekingalpha.com/pr/17030012-immucell-corporation-announces-pricing-3-million-public-offering-common-shares\" target=\"_blank\">prices </a>its public offering of 417,807 shares of common stock at $7.30 per share. Closing date is December 21.</li><li>Net proceeds will fund the completion of its Nisin production facility, expand production for First Defense Tri-Shield, hiring of additional sales managers, hiring a consultant to assist in regulatory approval of First Defense ex. North America and general corporate purposes.</li><li>Yesterday's close was $8.79.</li></ul><div class=\"tiny-share-widget\" data-id=\"3319075\" data-linked=\"ImmuCell prices stock offering at $7.30\" data-tweet=\"$ICCC - ImmuCell prices stock offering at $7.30 https://seekingalpha.com/news/3319075-immucell-prices-stock-offering-7_30?source=tweet\" data-url=\"https://seekingalpha.com/news/3319075-immucell-prices-stock-offering-7_30\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3319067\" data-ts=\"1513683302\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SOL\" target=\"_blank\">SOL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3319067-renesola-misses-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ReneSola misses on revenue</a></h4><ul><li>ReneSola (NYSE:<a href='https://seekingalpha.com/symbol/SOL' title='ReneSola Ltd.'>SOL</a>): Q3 EBITDA of $6.5M</li><li>Revenue of $36.29M (+23.9% Y/Y) <font color='red'>misses by $4.81M</font>.</li><li>Shares <font color='green'>+4.29%</font> PM.</li><li><a href=\"https://seekingalpha.com/pr/17030006-renesola-announces-third-quarter-2017-results-continuing-operations\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3319067\" data-linked=\"ReneSola misses on revenue\" data-tweet=\"$SOL - ReneSola misses on revenue https://seekingalpha.com/news/3319067-renesola-misses-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3319067-renesola-misses-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:35 AM </div></div></li>","count":70,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}